

## BACTERIAL VIRULENCE FACTORS AND USES THEREOF

5

## FIELD OF THE INVENTION

The invention relates to bacterial pathogens. More specifically, the invention relates to, in part, secreted proteins of bacterial pathogens and methods for their use.

## BACKGROUND OF THE INVENTION

10

*Escherichia coli* is an extremely versatile organism. In addition to being a member of the normal intestinal flora, strains of *E. coli* also cause bladder infections, meningitis, and diarrhea. Diarrheagenic *E. coli* include at least five types of *E. coli*, which cause various symptoms ranging from cholera-like diarrhea to extreme colitis. Each type of diarrheagenic *E. coli* possesses a particular set of virulence factors, including adhesins, invasins, and/or toxins, which are responsible for causing a specific type of diarrhea.

15

20

Enteropathogenic *E. coli* (EPEC), is a predominant cause of infantile diarrhea worldwide. EPEC disease is characterized by watery diarrhea of varying severity, with vomiting and fever often accompanying the fluid loss. In addition to isolated outbreaks in daycares and nurseries in developed countries, EPEC poses a major endemic health threat to young children (< 6 months) in developing countries. Worldwide, EPEC is the leading cause of bacterial mediated diarrhea in young children, and it has been estimated that EPEC kills several hundred thousand children per year.

25

30

Enterohemorrhagic *E. coli* (EHEC), also called Shiga toxin producing *E. coli* (STEC) or Vero toxin producing *E. coli* (VTEC), causes a more severe diarrhea than EPEC (enteric colitis) and in approximately 10% of cases, this disease progresses to an often fatal kidney disease, hemolytic uremic syndrome (HUS). EHEC O157:H7 is the most common serotype in Canada and the United States, and is associated with food and water poisoning (3). Other serotypes of EHEC also cause significant problems in Asia, Europe, and South America, and to a lesser extent in North America. EHEC colonizes cattle and causes A/E lesions, but does not cause disease in adult animals, and instead sheds organisms into the environment. This however

causes serious health problems as a relatively few EHEC are necessary to infect humans.

Unlike other *E. coli* diarrheas, such as enterotoxigenic *E. coli*, diarrhea caused by EHEC and EPEC is not mediated by a toxin. Instead, EPEC and EHEC bind to intestinal surfaces (EPEC the small bowel, EHEC the large bowel) and cause a characteristic histological lesion, called the attaching and effacing (A/E) lesion (8). A/E lesions are marked by dissolution of the intestinal brush border surface and loss of epithelial microvilli (effacement) at the sites of bacterial attachment. Once bound, bacteria reside upon cup-like projections or pedestals. Underlying this pedestal in the epithelial cell are several cytoskeletal components, including actin and actin associated cytoskeletal proteins. Formation of A/E lesions and actin-rich pedestals beneath attaching bacteria is the histopathological hallmark of A/E pathogens (1, 2). This pathology can be recapitulated in cultured cells *in vitro*, and pedestal formation can be viewed by a fluorescent actin staining assay (2, 11). Formation of the A/E lesion may be responsible for disruption of the brush border and microvilli, fluid secretion, and diarrhea.

EPEC and EHEC belong to a family of A/E pathogens, including several EPEC-like animal pathogens that cause disease in rabbits (REPEC), pigs (PEPEC), and mice (*Citrobacter rodentium*). These pathogens contain pathogenicity islands (PAIs) that encode specialized secretion systems and secreted virulence factors critical for disease. The genes required for the formation of A/E lesions are thought to be clustered together in a single chromosomal pathogenicity island known as the locus for enterocyte effacement (LEE), which includes regulatory elements, a type III secretion system (TTSS), secreted effector proteins, and their cognate chaperones (4-8).

The LEE contains 41 genes, making it one of the more complex PAIs. The main function of the LEE TTSS is to deliver effectors into host cells, where they subvert host cell functions and mediate disease (9, 10, 34). Five LEE-encoded effectors (Tir, EspG, EspF, Map, and EspH) have been identified (35-40). Tir (for translocated intimin receptor) is translocated into host cells where it binds host cytoskeletal and signaling proteins and initiates actin polymerization at the site of bacterial attachment (31, 44), resulting in formation of actin pedestal structures

underneath adherent bacteria, which directly interact with the extracellular loop of Tir via the bacterial outer membrane protein intimin. CesT plays a role as a chaperone for Tir stability and secretion (18, 19).

Four other LEE-encoded TTSS-translocated effectors have been characterized in A/E pathogens: EspH enhances elongation of actin pedestals (40); EspF plays a role in disassembly of tight junctions between intestinal epithelial cells (38); EspG is related to the *Shigella* microtubule-binding effector VirA (36, 55); and Map localizes to mitochondria (37), but also has a role in actin dynamics (48). Ler (for LEE encoded regulator) is the only LEE encoded regulator identified.

### SUMMARY OF THE INVENTION

This invention is based, in part, on the identification of several new common secreted proteins of A/E pathogens.

The invention provides, in one aspect, compositions including a polypeptide or fragment or variant thereof, or a cell culture supernatant including such a polypeptide where the substantially pure polypeptide includes an amino acid sequence substantially identical to the sequence of any one or more of SEQ ID NOs: 22-43, 59, or 73-84 or fragments or variants thereof. The invention also provides compositions including a nucleic acid molecule, where the nucleic acid molecule includes a nucleotide sequence substantially identical to the sequence of any one or more of SEQ ID NOs: 1-21 or 60-72; and compositions including a nucleotide sequence encoding a polypeptide substantially identical to the sequence of any one or more of SEQ ID NO: 22-43, or fragments thereof. The compositions may further include a physiologically acceptable carrier, or may further include an adjuvant. The compositions may also include a polypeptide or nucleic acid molecule such as EspA, EspB, EspD, EspP, Tir, Shiga toxin 1, Shiga toxin 2, or intimin. The polypeptides or nucleic acid molecules may be substantially pure.

The invention also provides, in alternative aspects, a bacterium or a preparation thereof, where the bacterium includes a mutation in a gene such as *nleA*, *nleB*, *nleC*, *nleD*, *nleE*, *nleF*, *nleG*, *nleH*, or a homologue thereof, or includes a mutation in the bacterial genome in a nucleotide sequence that is substantially identical to SEQ ID NOs: 1-21 or 60-72. In some embodiments, the bacterium may

be an A/E pathogen, such as enterohemorrhagic *E. coli* (EHEC; e.g., EHEC O157:H7 or EHEC O157:NM), enteropathogenic *E. coli* (EPEC; e.g., EPEC O127:H6), or *Citrobacter rodentium*. In some embodiments, the mutation may attenuate virulence, or may occur in a nucleotide sequence in the genome of the A/E pathogen that is substantially identical to a sequence selected from the group consisting of SEQ ID NOs: 1-21 or 60-72. The bacterium may be provided as a composition, in combination with an adjuvant. In some embodiments, the bacterium may be live. In some embodiments, the bacterium may be killed. The mode of administration may be oral or parenteral.

The invention also provides, in alternative aspects, a method of detecting the presence of an A/E pathogen in a sample, by providing a sample; and detecting the presence of: a nucleotide sequence substantially identical to a sequence selected from SEQ ID NOs: 1-21 or 60-72 or a fragment or variant thereof; a nucleotide sequence encoding a polypeptide sequence substantially identical to a sequence selected from SEQ ID NOs: 22-43, 59, or 73-84, or a polypeptide including an amino acid sequence substantially identical to a sequence selected from SEQ ID NOs: 22-43, 59, or 73-84 or a fragment or variant thereof, where the presence of the nucleotide sequence or the amino acid sequence indicates the presence of an A/E pathogen in the sample (e.g., egg, feces, blood, or intestine). The detecting may include contacting the nucleotide sequence with a probe or primer substantially identical to a sequence selected from the group consisting of SEQ ID NOs: 1-21 or 60-72, or a nucleotide sequence encoding a polypeptide sequence substantially identical to a sequence selected from the group consisting of SEQ ID NOs: 22-43, 59, or 73-84, or a portion thereof, or may include contacting the amino acid sequence with an antibody that specifically binds a sequence selected from the group consisting of SEQ ID NOs: 22-43, 59, or 73-84 or a fragment or variant thereof.

The invention also provides, in alternative aspects, methods for eliciting an immune response against an A/E pathogen or component thereof, or for reducing colonization or shedding of an A/E pathogen in a animal (e.g., a human; a ruminant, such as sheep (ovine subject), goats, cattle (bovine subject), etc.; or any other animal, e.g., pigs, rabbits, poultry (e.g., ducks, chicken, turkeys) etc.), by identifying a animal infected with, or at risk for infection by, an A/E pathogen; and administering to the



animal an effective amount of a composition including a polypeptide including an amino acid sequence substantially identical to the sequence of any one or more of SEQ ID NOs: 22-43, 59, or 73-8443; a nucleotide sequence encoding a polypeptide sequence substantially identical to a sequence selected from SEQ ID NOs: 22-43, 59, or 73-84; a nucleic acid molecule including a nucleotide sequence substantially identical to the sequence of any one or more of SEQ ID NOs: 1-21 or 60-72; or a cell culture supernatant including such polypeptides, thus eliciting an immune response, or reducing colonization or shedding of the A/E pathogen in the animal.

The invention also provides, in alternative aspects, a method of attenuating the virulence of an A/E pathogen, by providing an A/E pathogen; and mutating a gene such as *nleA*, *nleB*, *nleC*, *nleD*, *nleE*, *nleF*, *nleG*, or *nleH*, or a homologue thereof in the A/E pathogen, or mutating one or more of a nucleotide sequence in the genome of the A/E pathogen, where the nucleotide sequence is selected from SEQ ID NOs: 1- 21 or 60-72, thereby attenuating virulence.

The invention also provides, in alternative aspects, a method of screening for a compound that attenuates the virulence of an A/E pathogen, by providing a system (e.g., a cell, such as a EHEC, EPEC, or *C. rodentium* cell, an animal model, or an in vitro system) including: a polypeptide including an amino acid sequence substantially identical to the sequence of any one or more of SEQ ID NOs: 22-43, 59, or 73-84 or a fragment or variant thereof; a nucleotide sequence encoding a polypeptide sequence substantially identical to a sequence selected from SEQ ID NOs: 22-43, 59, or 73-84 or a fragment or variant thereof 3; or a nucleic acid molecule including a nucleotide sequence substantially identical to the sequence of any one or more of SEQ ID NOs: 1- 21 or 60-72 or a fragment or variant thereof ; providing a test compound; and determining whether the test compound modulates the expression, secretion, or biological activity of the polypeptide or the nucleic acid molecule, where a change, e.g., decrease in the expression, secretion, or biological activity of the polypeptide or the nucleic acid molecule indicates a compound that attenuates the virulence of an A/E pathogen.

The invention also provides, in alternative aspects, a method of producing a A/E pathogen virulence factor by providing a recombinant cell including a polypeptide including an amino acid sequence substantially identical to the sequence

of any one of SEQ ID NOs: 22-43, 59, or 73-84 or a fragment or variant thereof; a nucleotide sequence encoding a polypeptide sequence substantially identical to a sequence selected from the group consisting of SEQ ID NOs: 22-43, 59, or 73-84 or a fragment or variant thereof; or a nucleic acid molecule including a nucleotide  
5 sequence substantially identical to the sequence of any one of SEQ ID NOs: 1- 21 or 60-72 or a fragment or variant thereof; growing the recombinant cell under conditions that permit expression and/or secretion of the polypeptide, and optionally, isolating the polypeptide. In some embodiments, the polypeptide may be secreted from the cell.

10 The invention also provides, in alternative aspects, a method of treating or preventing infection by an A/E pathogen, by identifying a mammal having, or at risk for, an A/E pathogen infection; and administering to the mammal an effective amount of a compound that attenuates the virulence of an A/E pathogen, where the compound inhibits the expression or secretion of a polypeptide including an amino acid sequence  
15 substantially identical to the sequence of any one of SEQ ID NOs: 22-43, 59, or 73-84 or a fragment or variant thereof. In some embodiments, the compound may be an antisense nucleic acid molecule that is complementary to a nucleotide sequence substantially identical to the sequence of any one of SEQ ID NOs: 1- 21 or 60-72 or a fragment or variant thereof, or may be a siRNA.

20 The invention also provides, in alternative aspects, a recombinant polypeptide including an amino acid sequence substantially identical to the sequence of SEQ ID NOs: 22-43, 59, or 73-84, or an isolated nucleic acid molecule including a nucleotide sequence substantially identical to the sequence of SEQ ID NOs: 1-21 or 60-72; and/or a vector including such nucleotide sequences; and or a host cell (e.g., an A/E  
25 pathogen such as enterohemorrhagic *E. coli* (EHEC), enteropathogenic *E. coli* (EPEC), or *Citrobacter rodentium*, including such vectors. The vector may be capable or incapable of integrating into the genome of an A/E pathogen.

In alternative aspects, the invention also provides uses of the compositions, bacteria, polypeptides, or the nucleic acid molecules according to the invention, for  
30 the preparation of a medicament for eliciting an immune response against an A/E pathogen, or component thereof, or for reducing shedding or colonization of an A/E pathogen in an animal.

In alternative aspects, the invention also provides kits including a reagent for detecting an A/E pathogen in a sample and a package insert with instructions for detecting the A/E pathogen in the sample. The reagent may include a probe or primer probe or primer substantially identical to: a nucleotide sequence selected from the group consisting of one or more of SEQ ID NOs: 1- 21 or 60-72 or a fragment or variant thereof, or a nucleotide sequence encoding a polypeptide substantially identical to one or more of SEQ ID NO: 22-43, 59, 73-84 or a fragment or variant thereof, or an antibody that specifically binds a sequence selected from the group consisting of one or more of SEQ ID NOs: 22-43, 59, 73-84 or a fragment or variant thereof.

An "A/E pathogen" is a pathogen, for example a pathogenic *E. coli* bacterium, that can bind to the intestinal surfaces of an animal, for example, a mammal, e.g., cattle, sheep, goats, pigs, rabbits, dogs, cats, etc., or an avian species e.g., chickens, ducks, turkeys, etc., and cause a characteristic histological lesion, called the attaching and effacing (A/E) lesion (8). In general, an A/E pathogenic infection may result in diarrhea, enteric colitis, kidney disease (such as hemolytic uremic syndrome). However, infection with an A/E pathogen need not necessarily manifest in disease symptoms; a host mammal infected with an A/E pathogen may be a carrier of the pathogen and remain healthy and free of disease. Thus, mammals infected with, or at risk for infection by, an A/E pathogen include animals, e.g., farm animals, such as poultry animals, e.g. chickens, turkeys, ducks, or ruminants, e.g., cattle, sheep, goats, etc. or other farm animals, e.g., pigs, that do not manifest symptoms of disease, as well as include humans, who are susceptible to severe enteric disease as a result of A/E pathogenic infection.

Exemplary A/E pathogens include, without limitation, enterohemorrhagic *E. coli* (EHEC) (also known as Shiga toxin producing *E. coli* (STEC) or Vero toxin producing *E. coli* (VTEC), for example EHEC serotypes 0157 (e.g., EHEC O157:H7, the genomic sequence of which is described in Accession Nos. AE005594, AE005595, AP002566, AE 005174, NC\_002695, or NC\_002655), or 0158, 05, 08, 018, 026, 045, 048, 052, 055, 075, 076, 078, 084, 91, 0103, 0104, 0111, 0113, 0114, 0116, 0118, 0119, 0121, 0125, 028, 0145, 0146, 0163, 0165; enteropathogenic *E. coli* (EPEC); as well as pathogenic *E. coli* that infect mice (e.g., *Citrobacter rodentium*);

rabbits (e.g. RDEC-1 strains, such as O15:H<sup>-</sup>); pigs; sheep; dogs; and other mammals. Many strains of A/E pathogens are commercially available, for example, through the American Type Culture Collection (ATCC), Manassus, VA, USA. A/E pathogens may also be isolated from infected individuals for example, by direct plating on  
5 sorbitol MacConkey agar supplemented with cefixime and tellurite or immunomagnetic enrichment followed by plating on the same media (72, 107, 108).

A "protein," "peptide" or "polypeptide" is any chain of two or more amino acids, including naturally occurring or non-naturally occurring amino acids or amino acid analogues, regardless of post-translational modification (e.g., glycosylation or  
10 phosphorylation). An "amino acid sequence", "polypeptide", "peptide" or "protein" of the invention may include peptides or proteins that have abnormal linkages, cross links and end caps, non-peptidyl bonds or alternative modifying groups. Such modified peptides are also within the scope of the invention. The term "modifying group" is intended to include structures that are directly attached to the peptidic  
15 structure (e.g., by covalent coupling), as well as those that are indirectly attached to the peptidic structure (e.g., by a stable non-covalent association or by covalent coupling to additional amino acid residues, or mimetics, analogues or derivatives thereof, which may flank the core peptidic structure). For example, the modifying group can be coupled to the amino-terminus or carboxy-terminus of a peptidic  
20 structure, or to a peptidic or peptidomimetic region flanking the core domain. Alternatively, the modifying group can be coupled to a side chain of at least one amino acid residue of a peptidic structure, or to a peptidic or peptido- mimetic region flanking the core domain (e.g., through the epsilon amino group of a lysyl residue(s), through the carboxyl group of an aspartic acid residue(s) or a glutamic acid residue(s),  
25 through a hydroxy group of a tyrosyl residue(s), a serine residue(s) or a threonine residue(s) or other suitable reactive group on an amino acid side chain). Modifying groups covalently coupled to the peptidic structure can be attached by means and using methods well known in the art for linking chemical structures, including, for example, amide, alkylamino, carbamate or urea bonds.

30 The terms "nucleic acid" or "nucleic acid molecule" encompass both RNA (plus and minus strands) and DNA, including cDNA, genomic DNA, and synthetic (e.g., chemically synthesized) DNA. The nucleic acid may be double-stranded or

single-stranded. Where single-stranded, the nucleic acid may be the sense strand or the antisense strand. A nucleic acid molecule may be any chain of two or more covalently bonded nucleotides, including naturally occurring or non-naturally occurring nucleotides, or nucleotide analogs or derivatives. By "RNA" is meant a sequence of two or more covalently bonded, naturally occurring or modified ribonucleotides. One example of a modified RNA included within this term is phosphorothioate RNA. By "DNA" is meant a sequence of two or more covalently bonded, naturally occurring or modified deoxyribonucleotides. By "cDNA" is meant complementary or copy DNA produced from an RNA template by the action of RNA-dependent DNA polymerase (reverse transcriptase). Thus a "cDNA clone" means a duplex DNA sequence complementary to an RNA molecule of interest, carried in a cloning vector. By "complementary" is meant that two nucleic acids, e.g., DNA or RNA, contain a sufficient number of nucleotides which are capable of forming Watson-Crick base pairs to produce a region of double-strandedness between the two nucleic acids. Thus, adenine in one strand of DNA or RNA pairs with thymine in an opposing complementary DNA strand or with uracil in an opposing complementary RNA strand. It will be understood that each nucleotide in a nucleic acid molecule need not form a matched Watson-Crick base pair with a nucleotide in an opposing complementary strand to form a duplex. A nucleic acid molecule is "complementary" to another nucleic acid molecule if it hybridizes, under conditions of high stringency, with the second nucleic acid molecule.

A "cell culture supernatant," as used herein, refers generally to a supernatant derived from culturing a bacterium or other organism (e.g., yeast) or cell (e.g., insect cell) that is capable of secreting one or more of a polypeptide comprising an amino acid sequence substantially identical to the sequence of any one of SEQ ID NOs: 22-43, 59, 73-84 or a fragment or variant thereof, or an immunogenic portion thereof, into the cell culture medium. In some embodiments, the cell culture supernatant is substantially pure, i.e., substantially free of bacterial cells or the lysate of such cells. In some embodiments, the cell culture supernatant may also contain one or more of the EspA, EspB, EspD, Tir, intimin, Shiga toxin 1 or 2, or EspP polypeptides, or fragments or aggregates thereof.

The bacterium may be an A/E pathogen, for example, EHEC, EPEC, or *Citrobacter rodentium* that, in some embodiments, may be modified or mutated to preferentially express or secrete the proteins described herein, or may be some other bacterium, for example, a non-pathogenic bacterium, e.g., a non-pathogenic *E. coli* such as HB101, or a non-A/E pathogen, that has been modified or mutated, for example, by recombinant or other techniques, such that it secretes one or more of a protein described herein, for example, a polypeptide comprising an amino acid sequence substantially identical to the sequence of any one of SEQ ID NOs: 22-43, 59, 73-84 or a fragment or variant thereof, or an immunogenic portion thereof, into the cell culture medium. In some embodiments, the bacterium is not EHEC or EPEC. In some embodiments, where the bacterium is an A/E pathogen, it may also carry a further modification that impairs its ability to express or secrete a polypeptide (for example, EspA, EspB, EspD, Tir, intimin, Shiga toxin 1 or 2, or EspP) that it would normally secrete in the absence of the modification. In some embodiments, the other organism (e.g., yeast) or cell (e.g., insect cell) has been modified or mutated, for example, by recombinant or other techniques, such that it secretes one or more of a protein described herein, for example, a polypeptide comprising an amino acid sequence substantially identical to the sequence of any one of SEQ ID NOs: 22 through 43, or an immunogenic portion thereof, into the cell culture medium.

A compound is "substantially pure" or "isolated" when it is separated from the components that naturally accompany it. Typically, a compound is substantially pure when it is at least 10%, 20%, 30%, 40%, 50%, or 60%, or more generally at least 70%, 75%, 80%, 85%, 90%, 95%, or 99% by weight, of the total material in a sample. Thus, for example, a polypeptide that is chemically synthesised or produced by recombinant technology will be generally be substantially free from its naturally associated components. A polypeptide will also generally be substantially pure if it is separated from its naturally associated components by physical techniques, such as centrifugation, precipitation, column chromatography, gel electrophoresis, HPLC, etc.

A nucleic acid molecule will generally be substantially pure or "isolated" when it is not immediately contiguous with (i.e., covalently linked to) the coding sequences with which it is normally contiguous in the naturally occurring genome of the organism from which the DNA of the invention is derived. Therefore, an

“isolated” gene or nucleic acid molecule is intended to mean a gene or nucleic acid molecule which is not flanked by nucleic acid molecules which normally (in nature) flank the gene or nucleic acid molecule (such as in genomic sequences) and/or has been completely or partially purified from other transcribed sequences (as in a cDNA or RNA library). For example, an isolated nucleic acid of the invention may be substantially isolated with respect to the complex cellular milieu in which it naturally occurs. In some instances, the isolated material will form part of a composition (for example, a crude extract containing other substances), buffer system or reagent mix. In other circumstance, the material may be purified to essential homogeneity, for example as determined by PAGE or column chromatography such as HPLC. The term therefore includes, e.g., a recombinant nucleic acid incorporated into a vector, such as an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA or a genomic DNA fragment produced by PCR or restriction endonuclease treatment) independent of other sequences. It also includes a recombinant nucleic acid which is part of a hybrid gene encoding additional polypeptide sequences. Preferably, an isolated nucleic acid comprises at least about 50, 80 or 90 percent (on a molar basis) of all macromolecular species present. Thus, an isolated gene or nucleic acid molecule can include a gene or nucleic acid molecule which is synthesized chemically or by recombinant means. Recombinant DNA contained in a vector are included in the definition of “isolated” as used herein. Also, isolated nucleic acid molecules include recombinant DNA molecules in heterologous host cells, as well as partially or substantially purified DNA molecules in solution. In vivo and in vitro RNA transcripts of the DNA molecules of the present invention are also encompassed by “isolated” nucleic acid molecules. Such isolated nucleic acid molecules are useful in the manufacture of the encoded polypeptide, as probes for isolating homologous sequences (e.g., from other mammalian species), for gene mapping (e.g., by in situ hybridization with chromosomes), or for detecting expression of the gene in tissue (e.g., human tissue, such as peripheral blood), such as by Northern blot analysis.

A substantially pure compound can be obtained, for example, by extraction from a natural source; by expression of a recombinant nucleic acid molecule encoding a polypeptide compound; or by chemical synthesis. Purity can be measured using any

appropriate method such as column chromatography, gel electrophoresis, HPLC, etc. A substantially pure preparation of a cell, for example, a bacterial cell, is a preparation of cells in which contaminating cells that do not have the desired mutant genotype, or do not express or secrete the desired polypeptide in sufficient quantities, constitute less than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, of the total number of cells in the preparation.

Various genes and nucleic acid sequences of the invention may be recombinant sequences. The term "recombinant" means that something has been recombined, so that when made in reference to a nucleic acid construct the term refers to a molecule that is comprised of nucleic acid sequences that are joined together or produced by means of molecular biological techniques. The term "recombinant" when made in reference to a protein or a polypeptide refers to a protein or polypeptide molecule which is expressed using a recombinant nucleic acid construct created by means of molecular biological techniques. The term "recombinant" when made in reference to genetic composition refers to a gamete or progeny with new combinations of alleles that did not occur in the parental genomes. Recombinant nucleic acid constructs may include a nucleotide sequence which is ligated to, or is manipulated to become ligated to, a nucleic acid sequence to which it is not ligated in nature, or to which it is ligated at a different location in nature. Referring to a nucleic acid construct as 'recombinant' therefore indicates that the nucleic acid molecule has been manipulated using genetic engineering, i.e. by human intervention.

Recombinant nucleic acid constructs may for example be introduced into a host cell by transformation. Such recombinant nucleic acid constructs may include sequences derived from the same host cell species or from different host cell species, which have been isolated and reintroduced into cells of the host species. Recombinant nucleic acid construct sequences may become integrated into a host cell genome, either as a result of the original transformation of the host cells, or as the result of subsequent recombination and/or repair events.

As used herein, "heterologous" in reference to a nucleic acid or protein is a molecule that has been manipulated by human intervention so that it is located in a place other than the place in which it is naturally found. For example, a nucleic acid sequence from one species may be introduced into the genome of another species, or a



nucleic acid sequence from one genomic locus may be moved to another genomic or extrachromosomal locus in the same species. A heterologous protein includes, for example, a protein expressed from a heterologous coding sequence or a protein expressed from a recombinant gene in a cell that would not naturally express the protein.

A "substantially identical" sequence is an amino acid or nucleotide sequence that differs from a reference sequence only by one or more conservative substitutions, as discussed herein, or by one or more non-conservative substitutions, deletions, or insertions located at positions of the sequence that do not destroy the biological function of the amino acid or nucleic acid molecule. Such a sequence can be any integer from 10% to 99%, or more generally at least 10%, 20%, 30%, 40%, 50, 55% or 60%, or at least 65%, 75%, 80%, 85%, 90%, or 95%, or as much as 96%, 97%, 98%, or 99% identical at the amino acid or nucleotide level to the sequence used for comparison using, for example, the Align Program (96) or FASTA. For polypeptides, the length of comparison sequences may be at least 2, 5, 10, or 15 amino acids, or at least 20, 25, or 30 amino acids. In alternate embodiments, the length of comparison sequences may be at least 35, 40, or 50 amino acids, or over 60, 80, or 100 amino acids. For nucleic acid molecules, the length of comparison sequences may be at least 5, 10, 15, 20, or 25 nucleotides, or at least 30, 40, or 50 nucleotides. In alternate embodiments, the length of comparison sequences may be at least 60, 70, 80, or 90 nucleotides, or over 100, 200, or 500 nucleotides. Sequence identity can be readily measured using publicly available sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, or BLAST software available from the National Library of Medicine, or as described herein). Examples of useful software include the programs Pile-up and PrettyBox. Such software matches similar sequences by assigning degrees of homology to various substitutions, deletions, substitutions, and other modifications.

Alternatively, or additionally, two nucleic acid sequences may be "substantially identical" if they hybridize under high stringency conditions. In some embodiments, high stringency conditions are, for example, conditions that allow hybridization comparable with the hybridization that occurs using a DNA probe of at

least 500 nucleotides in length, in a buffer containing 0.5 M NaHPO<sub>4</sub>, pH 7.2, 7% SDS, 1 mM EDTA, and 1% BSA (fraction V), at a temperature of 65°C, or a buffer containing 48% formamide, 4.8x SSC, 0.2 M Tris-Cl, pH 7.6, 1x Denhardt's solution, 10% dextran sulfate, and 0.1% SDS, at a temperature of 42°C. (These are typical conditions for high stringency northern or Southern hybridizations.) Hybridizations may be carried out over a period of about 20 to 30 minutes, or about 2 to 6 hours, or about 10 to 15 hours, or over 24 hours or more. High stringency hybridization is also relied upon for the success of numerous techniques routinely performed by molecular biologists, such as high stringency PCR, DNA sequencing, single strand conformational polymorphism analysis, and in situ hybridization. In contrast to northern and Southern hybridizations, these techniques are usually performed with relatively short probes (e.g., usually about 16 nucleotides or longer for PCR or sequencing and about 40 nucleotides or longer for in situ hybridization). The high stringency conditions used in these techniques are well known to those skilled in the art of molecular biology (61).

A substantially identical sequence may for example be an amino acid sequence that is substantially identical to the sequence of any one of SEQ ID NOs: 22-43, 59, or 73-84, or a fragment or variant thereof, or a nucleotide sequence substantially identical to the sequence of any one of SEQ ID NOs: 1-21 or 60-72 or a fragment or variant thereof. In some embodiments, a substantially identical sequence may for example be a nucleotide sequence that is complementary to or hybridizes with the sequence of any one of SEQ ID NOs: 1-21 or 60-72 or a fragment or variant thereof. In some embodiments, a substantially identical sequence may be derived from an A/E pathogen.

A "probe" or "primer" is a single-stranded DNA or RNA molecule of defined sequence that can base pair to a second DNA or RNA molecule that contains a complementary sequence (the target). The stability of the resulting hybrid molecule depends upon the extent of the base pairing that occurs, and is affected by parameters such as the degree of complementarity between the probe and target molecule, and the degree of stringency of the hybridization conditions. The degree of hybridization stringency is affected by parameters such as the temperature, salt concentration, and concentration of organic molecules, such as formamide, and is determined by

methods that are known to those skilled in the art. Probes or primers specific for the nucleic acid sequences described herein, or portions thereof, may vary in length by any integer from at least 8 nucleotides to over 500 nucleotides, including any value in between, depending on the purpose for which, and conditions under which, the probe or primer is used. For example, a probe or primer may be at least 8, 10, 15, 20, or 25 nucleotides in length, or may be at least 30, 40, 50, or 60 nucleotides in length, or may be over 100, 200, 500, or 1000 nucleotides in length. Probes or primers specific for the nucleic acid molecules described herein can be any integer from 10% to 99%, or more generally at least 10%, 20%, 30%, 40%, 50, 55% or 60%, or at least 65%, 75%, 80%, 85%, 90%, or 95%, or as much as 96%, 97%, 98%, or 99% identical to the nucleic acid sequences described herein using for example the Align program (96).

Probes or primers can be detectably-labeled, either radioactively or non-radioactively, by methods that are known to those skilled in the art. Probes or primers can be used for methods involving nucleic acid hybridization, such as nucleic acid sequencing, nucleic acid amplification by the polymerase chain reaction, single stranded conformational polymorphism (SSCP) analysis, restriction fragment polymorphism (RFLP) analysis, Southern hybridization, northern hybridization, in situ hybridization, electrophoretic mobility shift assay (EMSA), and other methods that are known to those skilled in the art. Probes or primers may be derived from genomic DNA or cDNA, for example, by amplification, or from cloned DNA segments, or may be chemically synthesized.

A "mutation" includes any alteration in the DNA sequence, i.e. genome, of an organism, when compared with the parental strain. The alterations may arise spontaneously or by exposing the organism to a mutagenic stimulus, such as a mutagenic chemical, energy, radiation, recombinant techniques, mating, or any other technique use to alter DNA. A mutation may include an alteration in any of the nucleotide sequences described herein, or may include an alteration in a nucleotide sequence encoding any of the polypeptides described herein.

A mutation may "attenuate virulence" if, as a result of the mutation, the level of virulence of the mutant cell is decreased by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%, when compared with the parental strain. Decrease in virulence may also be measured by a decrease of at least 10%, 20%, 30%, 40%,

50%, 60%, 70%, 80%, 90%, or 100% in the expression of a polypeptide, for example, a polypeptide including an amino acid sequence substantially identical to the sequence of any one of SEQ ID NOs: 22-43, 59, or 73-84, or a fragment or variant thereof, , in the mutant strain when compared with the parental strain. Virulence of an A/E pathogen may be measured as described herein or as known in the art. Decrease in virulence may also be measured by a change of at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% in the biological activity of a polypeptide, for example, a polypeptide including an amino acid sequence substantially identical to the sequence of any one of SEQ ID NOs: 22-43, 59, or 73-84, or a fragment or variant thereof.

“Modulating” or “modulates” means changing, by either increase or decrease. The increase or decrease may be a change of any integer value between 10% and 90%, or of any integer value between 30% and 60%, or may be over 100%, when compared with a control or reference sample or compound.

A “test compound” is any naturally-occurring or artificially-derived chemical compound. Test compounds may include, without limitation, peptides, polypeptides, synthesised organic molecules, naturally occurring organic molecules, and nucleic acid molecules. A test compound can “compete” with a known compound such as any of the polypeptides or nucleic acid molecules described herein by, for example, interfering with virulence, or by interfering with any biological response induced by the known compound.

Generally, a test compound can exhibit any value between 10% and 200%, or over 500%, modulation when compared to a reference compound. For example, a test compound may exhibit at least any positive or negative integer from 10% to 200% modulation, or at least any positive or negative integer from 30% to 150% modulation, or at least any positive or negative integer from 60% to 100% modulation, or any positive or negative integer over 100% modulation. A compound that is a negative modulator will in general decrease modulation relative to a known compound, while a compound that is a positive modulator will in general increase modulation relative to a known compound.

A “vector” is a DNA molecule derived, for example, from a plasmid, bacteriophage, or mammalian or insect virus, or artificial chromosome, into which a

nucleic acid molecule, for example, a nucleotide sequence substantially identical to the sequence of any one of SEQ ID NOs: 1-21 or 60-72 or a fragment or variant thereof, may be inserted. A vector may contain one or more unique restriction sites and may be capable of autonomous replication in a defined host or vehicle organism such that the cloned sequence is reproducible. A vector may be a DNA expression vector, i.e., any autonomous element capable of directing the synthesis of a recombinant polypeptide, and thus may be used to express a polypeptide, for example a polypeptide comprising an amino acid sequence substantially identical to the sequence of any one of SEQ ID NOs: 22 - 43, 59, or 73-84, or a fragment or variant thereof, in a host cell. DNA expression vectors include bacterial plasmids and phages and mammalian and insect plasmids and viruses. A vector may be capable of integrating into the genome of the host cell, such that any modification introduced into the genome of the host cell by the vector becomes part of the genome of the host cell. A vector may be incapable of integrating into the genome of the host cell, and therefore remain as an autonomously replicating unit, such as a plasmid.

An antibody "specifically binds" an antigen when it recognises and binds the antigen, for example, a polypeptide including an amino acid sequence substantially identical to the sequence of any one of SEQ ID NOs: 22 - 43, 59, or 73-84, or a fragment or variant thereof, but does not substantially recognise and bind other molecules in a sample. Such an antibody has, for example, an affinity for the antigen which is at least 10, 100, 1000 or 10000 times greater than the affinity of the antibody for another reference molecule in a sample.

A "sample" can be any organ, tissue, cell, or cell extract isolated from a subject, such as a sample isolated from an animal infected with an A/E pathogen, or an animal to which one or more of the polypeptides or nucleic acid molecules of the invention, or immunogenic fragments thereof, have been administered. For example, a sample can include, without limitation, tissue (e.g., from a biopsy or autopsy), cells, blood, serum, milk, urine, stool, saliva, feces, eggs, mammalian cell culture or culture medium, or any other specimen, or any extract thereof, obtained from a patient (human or animal), test subject, or experimental animal. A sample may also include, without limitation, products produced in cell culture by normal or transformed cells (e.g., via recombinant DNA or monoclonal antibody technology). A "sample" may

also be a cell or cell line created under experimental conditions, that are not directly isolated from a subject. A sample can also be cell-free, artificially derived or synthesised.

The sample may be analyzed to detect the presence of a gene, genome, polypeptide, nucleic acid molecule derived from an A/E pathogen, or to detect a mutation in a gene derived from an A/E pathogen, or to detect expression levels of a gene or polypeptide derived from an A/E pathogen, or to determine the biological function of a gene or polypeptide derived from an A/E pathogen, using methods that are known in the art and/or described herein. For example, methods such as sequencing, single-strand conformational polymorphism (SSCP) analysis, or restriction fragment length polymorphism (RFLP) analysis of PCR products derived from a sample can be used to detect a mutation in a gene; ELISA or western blotting can be used to measure levels of polypeptide or antibody affinity; northern blotting can be used to measure mRNA levels, or PCR can be used to measure the level of a nucleic acid molecule.

An "immune response" includes, but is not limited to, one or more of the following responses in a mammal: induction of antibodies, B cells, T cells (including helper T cells, suppressor T cells, cytotoxic T cells,  $\gamma\delta$  T cells) directed specifically to the antigen(s) in a composition or vaccine, following administration of the composition or vaccine. An immune response to a composition or vaccine thus generally includes the development in the host mammal of a cellular and/or antibody-mediated response to the composition or vaccine of interest. In general, the immune response will result in prevention or reduction of infection by an A/E pathogen; resistance of the intestine to colonization by the A/E pathogen; or reduction in shedding of the A/E pathogen.

An "immunogenic fragment" of a polypeptide or nucleic acid molecule refers to an amino acid or nucleotide sequence that elicits an immune response. Thus, an immunogenic fragment may include, without limitation, any portion of any of the sequences described herein, or a sequence substantially identical thereto, that includes one or more epitopes (the site recognized by a specific immune system cell, such as a T cell or a B cell). For example, an immunogenic fragment may include, without limitation, peptides of any value between 6 and 60, or over 60, amino acids in length,

e.g., peptides of any value between 10 and 20 amino acids in length, or between 20 and 40 amino acids in length, derived from any one or more of the sequences described herein. Such fragments may be identified using standard methods known to those of skill in the art, such as epitope mapping techniques or antigenicity or  
 5 hydropathy plots using, for example, the Omega version 1.0 program from Oxford Molecular Group (see, for example, U. S. Patent No. 4,708,871)(76, 77, 81, 92, 73,).

#### BRIEF DESCRIPTION OF THE DRAWINGS

**Figures 1A-F** show nucleotide and amino acid sequences of NleA from *C. rodentium*, EPEC, and EHEC (SEQ ID NOs: 1-3 & 22-24).

**Figures 2A-J** show nucleotide and amino acid sequences of NleB and NleB2 from *C. rodentium*, EPEC, and EHEC (SEQ ID NOs: 4-7 & 25-29 & 60).

**Figures 3A-F** show nucleotide and amino acid sequences of NleC from *C. rodentium*, EPEC, and EHEC (SEQ ID NOs: 8-10 & 30-32).

**Figures 4A-F** show nucleotide and amino acid sequences of NleD from *C. rodentium*, EPEC, and EHEC (SEQ ID NOs: 11-13 & 33-35).

**Figures 5A-H** show nucleotide and amino acid sequences of NleE from *C. rodentium*, EPEC, and EHEC (SEQ ID NOs: 14-17 & 36-39).

**Figures 6A-H** show nucleotide and amino acid sequences of NleF from *C. rodentium*, EPEC, and EHEC (SEQ ID NOs: 18-21 & 40-43).

**Figure 7** shows an amino acid sequence alignment of *C. rodentium* Orf11/GrlA (SEQ ID NO: 56) with a positive transcriptional regulator, CaiF (SEQ ID NO: 57), and with the deduced amino acid sequence of an uncharacterized *Salmonella* protein (SEQ ID NO: 58). Underlined is the predicted helix-turn-helix motif  
 25 characteristic of DNA binding proteins. Identical amino acid residues are indicated by \*, while conserved changes are marked by +.

**Figure 8** shows complementation of *C. rodentium*  $\Delta orf11$  by *orf11* from *C. rodentium* (pCRorf11), EHEC (pEHorf11), or EPEC (pEPorf11), and  
 30 complementation of *C. rodentium*  $\Delta ler - \Delta orf11$  double mutant by *C. rodentium* *ler* or *orf11*.

**Figure 9** is a schematic diagram showing the relative locations of the O-islands containing the 6 newly identified effector genes in the EHEC O157:H7

genome. Also shown are the locations of the Shiga toxin genes (*stx*), the LEE, and the *inv-spa* TTSS. Note the association of many of these genes with prophages (CP-933 and BP-933).

**Figures 10A-B** show proteomic analysis of EHEC secreted proteins. **A.** 1-dimensional SDS-PAGE gel of total secreted proteins from wild type EHEC (wt) and the type III secretion mutant (*escN*<sup>-</sup>). Migration of molecular weight markers (in kDa) is indicated at the left of the gel. **B.** 2-dimensional gel of total secreted proteins from wild type EHEC. Migration of molecular weight markers (in kDa) is indicated at the left, and approximate pI values are shown on the top of the gel. Protein spots analyzed by mass spectroscopy (see Table I) are circled and numbered.

**Figures 11A-C** show NleA genomic organization, distribution and conservation. **A.** Graphic representation of the region surrounding *nleA* in the EHEC genome. Transcriptional direction of each ORF is indicated with an arrowhead. Annotation of ORFs is modified from (3). NleA is highlighted in bold. **B.** Southern blot analysis of genomic DNA from EPEC, EHEC, REPEC, *Citrobacter rodentium* (Citro.), and the non-pathogenic *E. coli* strain HB101. Each genomic DNA sample was digested with BamHI (lanes 1, 4, 7, 10, 13), EcoRI (lanes 2, 5, 8, 11, 14), and PstI (lanes 3, 6, 9, 12, 15). **C.** Multiple protein sequence alignment of NleA from EHEC, the prophage of an intimin-positive, non-O157 EHEC strain (O84:H4), EPEC, and *Citrobacter rodentium*. Identical residues are represented by a dot (.), amino acids absent from a particular sequence are represented with a dash (-). Two hydrophobic stretches that could be putative transmembrane domains are highlighted in bold in the EHEC sequence.

**Figure 12** shows a Western blot analysis of secreted proteins (left lanes) and bacterial pellets (right lanes) of wildtype (wt) EHEC and the type III secretion mutant (*escN*<sup>-</sup>) expressing pNleA-HA and the untransformed controls. Blots were probed with anti-HA (A.), anti-DnaK (B.), anti-Tir (C.).

**Figures 13A-B** show Type III secretion and translocation in  $\Delta nleA$  EHEC. **A.** SDS-PAGE gel of total secreted proteins from wildtype EHEC (wt) and the  $\Delta nleA$  mutant. Migration of molecular weight markers (in kDa) is indicated at the left of the gel. **B.** Western blot analysis of secreted proteins from wildtype EHEC (wt) and the



$\Delta nleA$  mutant with anti-NleA antiserum. Migration of molecular weight markers (in kDa) is indicated at the left of the gel.

**Figures 14A-B** show Western blot analysis of infected host cell fractions. **A.** HeLa cells were infected with wildtype (wt) or *escN*- EHEC expressing HA-tagged NleA and subjected to subcellular fractionation by differential centrifugation. Fractions analyzed were: bacteria, unbroken cells and cytoskeleton (low speed pellet), host cell cytosol (host cytosol), and host cell membranes (host membrane). Fractions were analysed by Western blot using anti-HA, anti-DnaK, anti-Calnexin, and anti-tubulin antibodies. **B.** Membrane fractions from cells infected with wildtype EHEC expressing HA-tagged NleA were isolated. Membrane fractions were then extracted on ice under high salt (1M NaCl), high pH (pH 11.4), neutral pH and isotonic salt (control), or neutral pH and isotonic salt containing 1% triton x100 (Triton X100) and recentrifuged to obtain soluble (S) and insoluble (P) membrane fractions. These fractions were subjected to Western blot analysis with anti-HA (top panel), anti-calnexin (middle panel), and anti-calreticulin (bottom panel) antibodies.

**Figures 15A-D** shows *Citrobacter rodentium* virulence studies in mice. **A.** Western blot of total bacterial extracts from wildtype *C. rodentium* (wt) and the  $\Delta nleA$  mutant, probed with anti-NleA antiserum. Migration of molecular weight markers (in kDa) is indicated at the left of the gel. **B.** Survival plots for C3H/HeJ mice infected with wildtype *C. rodentium* (black squares),  $\Delta nleA$  *C. rodentium* (open circles), and mice previously infected with the  $\Delta nleA$  mutant and subsequently challenged with wildtype *C. rodentium* (vertical bars). Mice were monitored daily during the course of infection and when any mice became moribund they were sacrificed immediately. Percentage of the starting number of mice in each group that were viable on each day is shown. **C.** *C. rodentium* titres from infected NIH swiss mice colons. Mice were infected with wildtype *C. rodentium* (black circles) or the  $\Delta nleA$  strain (open circles) and sacrificed at day 10 post infection. Colonic tissue and fecal pellets were homogenized and plated on MacConkey agar to determine the total *C. rodentium* burden in the mouse colon at the time of sacrifice. Each mouse in the experiment is represented by a single point. The mean of each group is indicated on the graph by horizontal bars. **D.** Colon and spleen weights of infected NIH swiss mice. Mice were infected with wildtype *C. rodentium* (black squares and triangles) or the  $\Delta nleA$

strain (open squares and triangles) and sacrificed at day 10 post infection. Colons (squares) and spleens (triangles) were dissected and weighed. Each mouse in the experiment is represented by a single point. The mean of each group is indicated on the graph by horizontal bars.

5           **Figures 16A-B** show nucleotide and amino acid sequences of NleG homolog from EHEC (SEQ ID NOs: 61 & 73).

**Figures 17A-B** show nucleotide and amino acid sequences of NleH1 from EHEC (SEQ ID NOs: 62 & 74).

10           **Figures 18A-B** show nucleotide and amino acid sequences of NleH2 from EHEC (SEQ ID NOs: 63 & 75).

**Figures 19A-B** show nucleotide and amino acid sequences of Z2076 from EHEC (SEQ ID NOs: 64 & 76).

**Figures 20A-B** show nucleotide and amino acid sequences of Z2149 from EHEC (SEQ ID NOs: 65 & 77).

15           **Figures 21A-B** show nucleotide and amino acid sequences of Z2150 from EHEC (SEQ ID NOs: 66 & 78).

**Figures 22A-B** show nucleotide and amino acid sequences of Z2151 from EHEC (SEQ ID NOs: 67 & 79).

20           **Figures 23A-B** show nucleotide and amino acid sequences of Z2337 from EHEC (SEQ ID NOs: 68 & 80).

**Figures 24A-B** show nucleotide and amino acid sequences of Z2338 from EHEC (SEQ ID NOs: 69 & 81).

**Figures 25A-B** show nucleotide and amino acid sequences of Z2339 from EHEC (SEQ ID NOs: 70 & 82).

25           **Figures 26A-B** show nucleotide and amino acid sequences of Z2560 from EHEC (SEQ ID NOs: 71 & 83).

**Figures 27A-B** show nucleotide and amino acid sequences of Z2976 from EHEC (SEQ ID NOs: 72 & 84).

## 30                                   DETAILED DESCRIPTION OF THE INVENTION

          We have identified several new common secreted proteins for A/E pathogens (Table 2) using a positive LEE regulator (Global Regulator of LEE Activator, or GrlA) which can be

used to increase secretion significantly, and has allowed us to functionally screen for proteins secreted via the LEE-encoded TTSS using a proteomics-based approach. These new proteins, termed Nle (non-LEE-encoded effector) A through H, are present in LEE-containing pathogens, and is absent from non-pathogenic strains of *E. coli* and from non-LEE pathogens are encoded outside the LEE by 3 PAIs that are present in A/E pathogens and have co-evolved with the LEE (3, 8). Identification of these proteins has, in some cases, enabled the assignment of function to ORFs of previously unknown function. An exemplary protein, NleA (p54), is a type III effector in A/E pathogens, including *C. rodentium*, EPEC, and EHEC, and plays a critical role in virulence. NleA is encoded in a phage-associated pathogenicity island within the EHEC genome, distinct from the LEE. The LEE-encoded TTSS directs translocation of NleA into host cells, where it localizes to the Golgi apparatus. *nleA* is present in LEE-containing pathogens, and is absent from non-pathogenic strains of *E. coli* and from non-LEE pathogens.

In some embodiments of the invention, these polypeptides and nucleic acid molecules encoding these polypeptides, or portions thereof, may be useful as vaccines, therapeutics, diagnostics, or drug screening tools for A/E pathogenic infections, or as reagents.

#### Polypeptides And Test Compounds

Compounds according to the invention include, without limitation, the polypeptides and nucleic acid molecules described in, for example, SEQ ID NOs: 1-56, 59-84, and fragments, analogues and variants thereof. Compounds according to the invention also include the products of the *orf11/grlA*, *nleA*, *nleB*, *nleB2*, *nleC*, *nleD*, *nleE*, *nleF*, *nleG*, *nleH* (*nle H1*, and/or *nle H2*) genes, or homologues thereof. Compounds according to the invention also include polypeptides and nucleic acid molecules described in, for example, the EHEC genome sequence (e.g. AE005174) as numbers Z0985 (NleB2), Z0986 (NleC), Z0990 (NleD), Z6020 (NleF), Z6024 (NleA), Z4328 (NleB), Z4329 (NleE), Z6025 (NleG homolog), Z6021 (NleH1), Z0989 (NleH2), Z2076, Z2149, Z2150, Z2151, Z2337, Z2338, Z2339, Z2560, Z2976, or L0043 (Orf11/Gr1A)(Accession No. AF071034), and fragments, analogues and variants thereof.

Compounds can be prepared by, for example, replacing, deleting, or inserting an amino acid residue at any position of a polypeptide described herein, with other

conservative amino acid residues, i.e., residues having similar physical, biological, or chemical properties, and screening, for example, for the ability of the compound to attenuate virulence. In some embodiments of the invention, compounds of the invention include antibodies that specifically bind to the polypeptides described

5 herein, for example, SEQ ID NOs: 22-43, 59, or 73-84.

It is well known in the art that some modifications and changes can be made in the structure of a polypeptide without substantially altering the biological function of that peptide, to obtain a biologically equivalent polypeptide. In one aspect of the invention, polypeptides of the present invention also extend to biologically equivalent peptides or "variants" that differ from a portion of the sequence of the polypeptides of the present invention by conservative amino acid substitutions, or differ by non-conservative substitutions that do not affect biological function e.g., virulence. As used herein, the term "conserved amino acid substitutions" refers to the substitution of one amino acid for another at a given location in the peptide, where the substitution

10 can be made without substantial loss of the relevant function. In making such changes, substitutions of like amino acid residues can be made on the basis of relative similarity of side-chain substituents, for example, their size, charge, hydrophobicity, hydrophilicity, and the like, and such substitutions may be assayed for their effect on the function of the peptide by routine testing.

As used herein, the term "amino acids" means those L-amino acids commonly found in naturally occurring proteins, D-amino acids and such amino acids when they have been modified. Accordingly, amino acids of the invention may include, for example: 2-Aminoadipic acid; 3-Aminoadipic acid; beta-Alanine; beta-Aminopropionic acid; 2-Aminobutyric acid; 4-Aminobutyric acid; piperidinic acid; 6-

25 Aminocaproic acid; 2-Aminoheptanoic acid; 2-Aminoisobutyric acid; 3-Aminoisobutyric acid; 2-Aminopimelic acid; 2,4 Diaminobutyric acid; Desmosine; 2,2'-Diaminopimelic acid; 2,3-Diaminopropionic acid; N-Ethylglycine; N-Ethylasparagine; Hydroxylysine; allo-Hydroxylysine; 3-Hydroxyproline; 4-Hydroxyproline; Isodesmosine; allo-Isoleucine; N-Methylglycine; sarcosine; N-

30 Methylisoleucine; 6-N-methyllysine; N-Methylvaline; Norvaline; Norleucine; and Ornithine.

In some embodiments, conserved amino acid substitutions may be made where an amino acid residue is substituted for another having a similar hydrophilicity value (e.g., within a value of plus or minus 2.0, or plus or minus 1.5, or plus or minus 1.0, or plus or minus 0.5), where the following may be an amino acid having a hydrophobic index of about -1.6 such as Tyr (-1.3) or Pro (-1.6) are assigned to amino acid residues (as detailed in United States Patent No. 4,554,101, incorporated herein by reference): Arg (+3.0); Lys (+3.0); Asp (+3.0); Glu (+3.0); Ser (+0.3); Asn (+0.2); Gln (+0.2); Gly (0); Pro (-0.5); Thr (-0.4); Ala (-0.5); His (-0.5); Cys (-1.0); Met (-1.3); Val (-1.5); Leu (-1.8); Ile (-1.8); Tyr (-2.3); Phe (-2.5); and Trp (-3.4).

In alternative embodiments, conservative amino acid substitutions may be made where an amino acid residue is substituted for another having a similar hydrophobic index (e.g., within a value of plus or minus 2.0, or plus or minus 1.5, or plus or minus 1.0, or plus or minus 0.5). In such embodiments, each amino acid residue may be assigned a hydrophobic index on the basis of its hydrophobicity and charge characteristics, as follows: Ile (+4.5); Val (+4.2); Leu (+3.8); Phe (+2.8); Cys (+2.5); Met (+1.9); Ala (+1.8); Gly (-0.4); Thr (-0.7); Ser (-0.8); Trp (-0.9); Tyr (-1.3); Pro (-1.6); His (-3.2); Glu (-3.5); Gln (-3.5); Asp (-3.5); Asn (-3.5); Lys (-3.9); and Arg (-4.5).

In alternative embodiments, conservative amino acid substitutions may be made using publicly available families of similarity matrices (60, 70, 102, 103, 94, 104, 86). The PAM matrix is based upon counts derived from an evolutionary model, while the Blosum matrix uses counts derived from highly conserved blocks within an alignment. A similarity score of above zero in either of the PAM or Blosum matrices may be used to make conservative amino acid substitutions.

In alternative embodiments, conservative amino acid substitutions may be made where an amino acid residue is substituted for another in the same class, where the amino acids are divided into non-polar, acidic, basic and neutral classes, as follows: non-polar: Ala, Val, Leu, Ile, Phe, Trp, Pro, Met; acidic: Asp, Glu; basic: Lys, Arg, His; neutral: Gly, Ser, Thr, Cys, Asn, Gln, Tyr.

Conservative amino acid changes can include the substitution of an L-amino acid by the corresponding D-amino acid, by a conservative D-amino acid, or by a naturally-occurring, non-genetically encoded form of amino acid, as well as a

conservative substitution of an L-amino acid. Naturally-occurring non-genetically encoded amino acids include beta-alanine, 3-amino-propionic acid, 2,3-diamino propionic acid, alpha-aminoisobutyric acid, 4-amino-butyric acid, N-methylglycine (sarcosine), hydroxyproline, ornithine, citrulline, t-butylalanine, t-butylglycine, N-methylisoleucine, phenylglycine, cyclohexylalanine, norleucine, norvaline, 2-naphthylalanine, pyridylalanine, 3-benzothienyl alanine, 4-chlorophenylalanine, 2-fluorophenylalanine, 3-fluorophenylalanine, 4-fluorophenylalanine, penicillamine, 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid, beta-2-thienylalanine, methionine sulfoxide, homoarginine, N-acetyl lysine, 2-amino butyric acid, 2-amino butyric acid, 2,4,-diamino butyric acid, p-aminophenylalanine, N-methylvaline, homocysteine, homoserine, cysteic acid, epsilon-amino hexanoic acid, delta-amino valeric acid, or 2,3-diaminobutyric acid.

In alternative embodiments, conservative amino acid changes include changes based on considerations of hydrophilicity or hydrophobicity, size or volume, or charge. Amino acids can be generally characterized as hydrophobic or hydrophilic, depending primarily on the properties of the amino acid side chain. A hydrophobic amino acid exhibits a hydrophobicity of greater than zero, and a hydrophilic amino acid exhibits a hydrophilicity of less than zero, based on the normalized consensus hydrophobicity scale of Eisenberg *et al.* (71). Genetically encoded hydrophobic amino acids include Gly, Ala, Phe, Val, Leu, Ile, Pro, Met and Trp, and genetically encoded hydrophilic amino acids include Thr, His, Glu, Gln, Asp, Arg, Ser, and Lys. Non-genetically encoded hydrophobic amino acids include t-butylalanine, while non-genetically encoded hydrophilic amino acids include citrulline and homocysteine.

Hydrophobic or hydrophilic amino acids can be further subdivided based on the characteristics of their side chains. For example, an aromatic amino acid is a hydrophobic amino acid with a side chain containing at least one aromatic or heteroaromatic ring, which may contain one or more substituents such as -OH, -SH, -CN, -F, -Cl, -Br, -I, -NO<sub>2</sub>, -NO, -NH<sub>2</sub>, -NHR, -NRR, -C(O)R, -C(O)OH, -C(O)OR, -C(O)NH<sub>2</sub>, -C(O)NHR, -C(O)NRR, etc., where R is independently (C<sub>1</sub>-C<sub>6</sub>) alkyl, substituted (C<sub>1</sub>-C<sub>6</sub>) alkyl, (C<sub>1</sub>-C<sub>6</sub>) alkenyl, substituted (C<sub>1</sub>-C<sub>6</sub>) alkenyl, (C<sub>1</sub>-C<sub>6</sub>) alkynyl, substituted (C<sub>1</sub>-C<sub>6</sub>) alkynyl, (C<sub>5</sub>-C<sub>20</sub>) aryl, substituted (C<sub>5</sub>-C<sub>20</sub>) aryl, (C<sub>6</sub>-C<sub>26</sub>) alkaryl, substituted (C<sub>6</sub>-C<sub>26</sub>) alkaryl, 5-20 membered heteroaryl, substituted 5-20

membered heteroaryl, 6-26 membered alkheteroaryl or substituted 6-26 membered alkheteroaryl. Genetically encoded aromatic amino acids include Phe, Tyr, and Trp, while non-genetically encoded aromatic amino acids include phenylglycine, 2-naphthylalanine, beta-2-thienylalanine, 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid, 4-chlorophenylalanine, 2-fluorophenylalanine, 3-fluorophenylalanine, and 4-fluorophenylalanine.

An apolar amino acid is a hydrophobic amino acid with a side chain that is uncharged at physiological pH and which has bonds in which a pair of electrons shared in common by two atoms is generally held equally by each of the two atoms (i.e., the side chain is not polar). Genetically encoded apolar amino acids include Gly, Leu, Val, Ile, Ala, and Met, while non-genetically encoded apolar amino acids include cyclohexylalanine. Apolar amino acids can be further subdivided to include aliphatic amino acids, which is a hydrophobic amino acid having an aliphatic hydrocarbon side chain. Genetically encoded aliphatic amino acids include Ala, Leu, Val, and Ile, while non-genetically encoded aliphatic amino acids include norleucine.

A polar amino acid is a hydrophilic amino acid with a side chain that is uncharged at physiological pH, but which has one bond in which the pair of electrons shared in common by two atoms is held more closely by one of the atoms. Genetically encoded polar amino acids include Ser, Thr, Asn, and Gln, while non-genetically encoded polar amino acids include citrulline, N-acetyl lysine, and methionine sulfoxide.

An acidic amino acid is a hydrophilic amino acid with a side chain pKa value of less than 7. Acidic amino acids typically have negatively charged side chains at physiological pH due to loss of a hydrogen ion. Genetically encoded acidic amino acids include Asp and Glu. A basic amino acid is a hydrophilic amino acid with a side chain pKa value of greater than 7. Basic amino acids typically have positively charged side chains at physiological pH due to association with hydronium ion. Genetically encoded basic amino acids include Arg, Lys, and His, while non-genetically encoded basic amino acids include the non-cyclic amino acids ornithine, 2,3,-diaminopropionic acid, 2,4-diaminobutyric acid, and homoarginine.

It will be appreciated by one skilled in the art that the above classifications are not absolute and that an amino acid may be classified in more than one category. In

addition, amino acids can be classified based on known behaviour and or characteristic chemical, physical, or biological properties based on specified assays or as compared with previously identified amino acids. Amino acids can also include bifunctional moieties having amino acid-like side chains.

5           Conservative changes can also include the substitution of a chemically derivatised moiety for a non-derivatised residue, by for example, reaction of a functional side group of an amino acid. Thus, these substitutions can include compounds whose free amino groups have been derivatised to amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, 10 chloroacetyl groups or formyl groups. Similarly, free carboxyl groups can be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides, and side chains can be derivatized to form O-acyl or O-alkyl derivatives for free hydroxyl groups or N-im-benzylhistidine for the imidazole nitrogen of histidine. Peptide analogues also include amino acids that have been chemically 15 altered, for example, by methylation, by amidation of the C-terminal amino acid by an alkylamine such as ethylamine, ethanolamine, or ethylene diamine, or acylation or methylation of an amino acid side chain (such as acylation of the epsilon amino group of lysine). Peptide analogues can also include replacement of the amide linkage in the peptide with a substituted amide (for example, groups of the formula  $-C(O)-NR$ , 20 where R is  $(C_1-C_6)$  alkyl,  $(C_1-C_6)$  alkenyl,  $(C_1-C_6)$  alkynyl, substituted  $(C_1-C_6)$  alkyl, substituted  $(C_1-C_6)$  alkenyl, or substituted  $(C_1-C_6)$  alkynyl) or isostere of an amide linkage (for example,  $-CH_2NH-$ ,  $-CH_2S-$ ,  $-CH_2CH_2-$ ,  $-CH=CH-$  (cis and trans),  $-C(O)CH_2-$ ,  $-CH(OH)CH_2-$ , or  $-CH_2SO-$ ).

25           The compound can be covalently linked, for example, by polymerisation or conjugation; to form homopolymers or heteropolymers. Spacers and linkers, typically composed of small neutral molecules, such as amino acids that are uncharged under physiological conditions, can be used. Linkages can be achieved in a number of ways. For example, cysteine residues can be added at the peptide termini, and multiple peptides can be covalently bonded by controlled oxidation. Alternatively, 30 heterobifunctional agents, such as disulfide/amide forming agents or thioether/amide forming agents can be used. The compound can also be linked to a another compound



that can for example modulate an immunogenic response. The compound can also be constrained, for example, by having cyclic portions.

Peptides or peptide analogues can be synthesised by standard chemical techniques, for example, by automated synthesis using solution or solid phase synthesis methodology. Automated peptide synthesisers are commercially available and use techniques well known in the art. Peptides and peptide analogues can also be prepared using recombinant DNA technology using standard methods such as those described in, for example, Sambrook, *et al.* (110) or Ausubel *et al.* (111). In general, candidate compounds are identified from large libraries of both natural products or synthetic (or semi-synthetic) extracts or chemical libraries according to methods known in the art. Those skilled in the field of drug discovery and development will understand that the precise source of test extracts or compounds is not critical to the method(s) of the invention. Accordingly, virtually any number of chemical extracts or compounds can be screened using the exemplary methods described herein. Examples of such extracts or compounds include, but are not limited to, plant-, fungal-, prokaryotic- or animal-based extracts, fermentation broths, and synthetic compounds, as well as modification of existing compounds. Numerous methods are also available for generating random or directed synthesis (e.g., semi-synthesis or total synthesis) of any number of chemical compounds, including, but not limited to, saccharide-, lipid-, peptide-, and nucleic acid-based compounds. Synthetic compound libraries are commercially available. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant, and animal extracts are commercially available from a number of sources, including Biotics (Sussex, UK), Xenova (Slough, UK), Harbor Branch Oceanographic Institute (Ft. Pierce, FL, USA), and PharmaMar, MA, USA. In addition, natural and synthetically produced libraries of, for example, A/E pathogen polypeptides, are produced, if desired, according to methods known in the art, e.g., by standard extraction and fractionation methods. Furthermore, if desired, any library or compound is readily modified using standard chemical, physical, or biochemical methods.

When a crude extract is found to modulate virulence, further fractionation of the positive lead extract is necessary to isolate chemical constituents responsible for the observed effect. Thus, the goal of the extraction, fractionation, and purification

process is the careful characterization and identification of a chemical entity within the crude extract having virulence modulatory properties. The same assays described herein for the detection of activities in mixtures of compounds can be used to purify the active component and to test derivatives thereof. Methods of fractionation and purification of such heterogeneous extracts are known in the art. If desired, compounds shown to be useful agents for treatment are chemically modified according to methods known in the art. Compounds identified as being of therapeutic, prophylactic, diagnostic, or other value may be subsequently analyzed using a *Citrobacter* or bovine model for A/E pathogenic infection, or any other animal model for A/E pathogenic infection.

### Vaccines

A "vaccine" is a composition that includes materials that elicit a desired immune response. A vaccine may select, activate or expand memory B and T cells of the immune system to, for example, enable the elimination of infectious agents, such as A/E pathogens, or components thereof. In some embodiments, a vaccine includes a suitable carrier, such as an adjuvant, which is an agent that acts in a non-specific manner to increase the immune response to a specific antigen, or to a group of antigens, enabling the reduction of the quantity of antigen in any given vaccine dose, or the reduction of the frequency of dosage required to generate the desired immune response. A desired immune response may include full or partial protection against shedding of (presence in feces of an infected animal, e.g., mammal) or colonization (presence in the intestine of an infected animal, e.g., mammal) by an A/E pathogen. For example, a desired immune response may include any value from between 10% to 100%, e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, protection against shedding of or colonization by an A/E pathogen in a vaccinated animal when compared to a non-vaccinated animal.

Vaccines according to the invention may include the polypeptides and nucleic acid molecules described herein, or immunogenic fragments thereof, and may be administered using any form of administration known in the art or described herein. In some embodiments of the invention, the vaccine may include a live A/E pathogen, a killed A/E pathogen, or components thereof. Live A/E pathogens, which may be

administered in the form of an oral vaccine, may contain non-reversible genetic alterations that affect the virulence of the A/E pathogen, but not its induction of an immune response. A live vaccine may be capable of colonizing the intestines of the inoculated animal, e.g., mammal.

5 In some embodiments, the polypeptides and nucleic acid molecules described herein, or immunogenic fragments thereof, or the mutated bacteria (e.g., attenuated bacteria) described herein may be administered to poultry, e.g., chicken, ducks, turkeys, etc., so as to elicit an immune response e.g., raise antibodies, in the poultry. Eggs, or products thereof, obtained from such poultry, that exhibit an immune  
10 response against the the polypeptides and nucleic acid molecules described herein, or immunogenic fragments thereof, may be administered to an animal, e.g., humans, cattle, goats, sheep, etc., to elicit an immune response to the polypeptides and nucleic acid molecules described herein, or immunogenic fragments thereof, in the animal. Methods of raising antibodies in poultry, and administering such antibodies, are  
15 described in for example, US Patent 5,750,113 issued to Cook, May 12, 1998; US Patent 6,730,822 issued to Ivarie, et al. May 4, 2004; and publications 113-117 cited herein.

The vaccines according to the invention may be further supplemented by the addition of recombinant or purified antigens such as EspA, EspB, EspD, EspP, Tir,  
20 Shiga toxin 1 or 2, and/or intimin, using standard techniques known in the art. For example, the recombinant production and use of EHEC O157:H7 proteins such as EspA, Tir, EspB, and intimin have been described (PCT Publication No. WO 97/40063; PCT Publication No. WO 99/24576; 51).

### 25 Cell Culture

A/E pathogens may be grown according to any methods known in the art or described herein. For example, A/E pathogens may be first grown in Luria-Bertani (LB) medium for a period of about 8 to 48 hours, or about 12 to 24 hours, and then diluted about 1: 5 to 1: 100, e.g., 1:67, or about 1: 5 to 1: 25, or about 1:10, into M-9  
30 minimal medium supplemented with 20-100 mM NaHCO<sub>2</sub> or NaHCO<sub>3</sub>, or about 30-50 mM, or about 44 mM NaHCO<sub>2</sub> or NaHCO<sub>3</sub>; 4-20 mM MgSO<sub>4</sub>, or about 5-10 mM; or about 0.8 mM to 8 mM MgSO<sub>4</sub>, 0. 1 to 1. 5% glucose, or about 0.2 to 1 %, or about

0.4% glucose and 0.05 to 0.5% Casamino Acids, or about 0.07 to 0.2%, or about 0.1% Casamino Acids. Cultures are generally maintained at about 37 degrees C, optionally in 2-10% CO<sub>2</sub>, or optionally in about 5% CO<sub>2</sub>, and grown to an optical density of about 600nm of 0.7 to 0.8. Whole cells are then removed by any suitable means, e.g.,  
5 microfiltration or centrifugation and the supernatant can be concentrated, e. g., 10-1000 fold or more, such as 100-fold, using dialysis, ultrafiltration and the like. Total protein is easily determined using methods well known in the art.

Cell culture supernatants may be produced using cultures of any A/E pathogen, for example, EHEC, as described herein or known to those of skill in the  
10 art, including wild type or mutant A/E pathogens. Generally, the A/E pathogen is cultured in a suitable medium, under conditions that favor type III antigen secretion (U. S. Patent Nos. 6,136,554 and 6,165,743)(51, 74).

#### Isolation and Identification of Additional Genes

15 Based on the nucleotide and amino acid sequences described herein, for example, in SEQ ID NOs:1- 56 or 59-84, the isolation and identification of additional genes is made possible using standard techniques. Any A/E pathogen can serve as the source for such genes.

20 In some embodiments, the nucleic acid sequences described herein may be used to design probes or primers, including degenerate oligonucleotide probes or primers, based upon the sequence of either DNA strand. The probes or primers may then be used to screen genomic or cDNA libraries for genes from other A/E pathogens, using standard amplification or hybridization techniques.

25 In some embodiments, the amino acid sequences described herein may be used to generate antibodies or other reagents that be used to screen for polypeptides from A/E pathogens that bind these antibodies.

30 In some embodiments, binding partners may be identified by tagging the polypeptides of the invention (e.g., those substantially identical to SEQ ID NOs; 22-43, 59, or 73-84) with an epitope sequence (e.g., FLAG or 2HA), and delivering it into host cells, either by transfection with a suitable vector containing a nucleic acid sequence encoding a polypeptide of the invention, or by endogenous bacterial type III delivery, followed by immunoprecipitation and identification of the binding partner.

HeLa cells may be infected with strains expressing the FLAG or 2HA fusions, followed by lysis and immunoprecipitation with anti-FLAG or anti-2HA antibodies. Binding partners may be identified by mass spectroscopy. If the polypeptide of the invention is not produced in sufficient quantities, such a method may not deliver enough tagged protein to identify its partner. As part of a complementary approach, each polypeptide of the invention may be cloned into a mammalian transfection vector fused to, for example, 2HA, GFP and/or FLAG. Following transfection, HeLa cells may be lysed and the tagged polypeptide immunoprecipitated. The binding partner may be identified by SDS PAGE followed by mass spectroscopy.

In some embodiments, polypeptides of the invention may be tagged, overproduced, and used on affinity columns and in immunoprecipitations to identify and/or confirm identified target compounds. FLAG, HA, and/or His tagged proteins can be used for such affinity columns to pull out host cell factors from cell extracts, and any hits may be validated by standard binding assays, saturation curves, and other methods as described herein or known to those of skill in the art.

In some embodiments, a bacterial two hybrid system may be used to study protein-protein interactions. The nucleic acid sequences described herein, or sequences substantially identical thereto, can be cloned into the pBT bait plasmid of the two hybrid system, and a commercially available murine spleen library of  $5 \times 10^6$  independent clones, may be used as the target library for the baits. Potential hits may be further characterized by recovering the plasmids and retransforming to reduce false positives resulting from clonal bait variants and library target clones which activate the reporter genes independent of the cloned bait. Reproducible hits may be studied further as described herein.

In some embodiments, an A/E pathogenic strain expressing GrlA, for example, an EHEC O157 strain expressing a cloned GrlA, may be used for proteomic analysis of A/E type III secreted proteomes, using for example, 2D gel analysis of the supernatants. In addition, complete A/E pathogen (e.g., EHEC arrays) may be used to define which genes are regulated by GrlA. Virulence may be assayed as described herein or as known to those of skill in the art.

Once coding sequences have been identified, they may be isolated using standard cloning techniques, and inserted into any suitable vector or replicon for,

example, production of polypeptides. Such vectors and replicons include, without limitation, bacteriophage X (*E. coli*), pBR322 (*E. coli*), pACYC177 (*E. coli*), pKT230 (gram-negative bacteria), pGV1 106 (gram-negative bacteria), pLAFR1 (gram-negative bacteria), pME290 (non-*E. coli* gram-negative bacteria), pHV14 (*E. coli* and *Bacillus subtilis*), pBD9 (*Bacillus*), pIJ61 (*Streptomyces*), pUC6 (*Streptomyces*), YIp5 (*Saccharomyces*), YCpl9 (*Saccharomyces*) or bovine papilloma virus (mammalian cells).

In general, the polypeptides of the invention may be produced in any suitable host cell transformed or transfected with a suitable vector (69). The method of transformation or transfection and the choice of expression vehicle will depend on the host system selected. A wide variety of expression systems may be used, and the precise host cell used is not critical to the invention. For example, a polypeptide according to the invention may be produced in a prokaryotic host (e.g., *E. coli*) or in a eukaryotic host (e.g., *Saccharomyces cerevisiae*, insect cells, e.g., Sf21 cells, or mammalian cells, e.g., NIH 3T3, HeLa, or COS cells). Such cells are available from a wide range of sources (e.g., the American Type Culture Collection, Manassus, VA.). Bacterial expression systems for polypeptide production include the *E. coli* pET expression system (Novagen, Inc., Madison, Wis.), and the pGEX expression system (Pharmacia).

#### Assays

Candidate compounds, including polypeptides, nucleic acid molecules, and small molecules, can be screened and tested using a variety of techniques described herein or known to those of skill in the art. A compound that reduces the level of expression of any of the polypeptides or nucleic acid molecules of the invention may be useful, for example, as a therapeutic against an A/E pathogenic infection.

Screening assays may be conducted, for example, by measuring gene expression by standard Northern blot analysis, using any appropriate nucleic acid fragment according to the invention as a hybridization probe, where the level of gene expression in the presence of the candidate compound is compared to the level of gene expression in the absence of the candidate compound. Alternatively, or additionally, the effect of a candidate compound may

be determined at the level of polypeptide expression or secretion, using for example immunoprecipitation or Western blotting approaches.

Other assays may be conducted as follows:

5           Confirmation Of Type III Secretion And Translocation Into Host Cells

To determine which of the candidate compounds require the TTSS for secretion, each gene or portion thereof may be fused to a FLAG at its C terminus, and supernatants collected from WT and TTSS mutants, for example, WT EHEC and the isogenic *escN* type III mutant as described herein or known in the art. Alternate methods to determine secretion include  
10 examination of supernatants for loss of secreted product in the mutant strain, or raising antibodies to the protein and using Western analysis of WT and type III supernatants. To confirm that none of the proteins of interest are TTSS components, supernatants from each of the candidate compounds, grown under type III inducing conditions may be examined for type III secretion. The LEE TTSS secretes two classes of proteins: the translocon (EspA, B,  
15 and D) which is assembled on the bacterial cell surface, and effectors, which are translocated directly into host cells. Candidate compounds may be tested to determine whether they are effectors or translocators. For example, FLAG-tagged putative effectors in EHEC or other A/E pathogens may be used to infect cultured HeLa epithelial cells, and examined by immunofluorescence microscopy after staining with anti-FLAG antibodies. Such  
20 visualization usually demonstrates bacterial delivery into the host cell, and often indicates which organelle the effector is targeted to (e.g. Tir to membrane, NleA to Golgi). Antibodies to various cellular compartments can be used these to confirm the localization. To complement the visualization, infected HeLa cells can be fractionated into cytosol, insoluble, and membrane fractions using known fractionation methods (30), and Western analysis  
25 performed using anti-FLAG antibodies to define which cellular fraction the effector is targeted to. As a control, cells may be infected with the tagged effector expressed in a TTSS defective strain. If targeted to the membrane fraction, high salt or alkaline pH treatment can be used to determine if it is an integral membrane protein. If the candidate compound is expressed at a low level, and detecting translocation by immunofluorescence is difficult,  
30 genetic fusions can be made to adenylate cyclase, an enzyme which requires a mammalian cytoplasmic cofactor (calmodulin) for activity (87).

Effects on pedestal formation and uptake.

Given that actin condensation and pedestal formation are hallmarks of A/E pathogens, candidate compounds can be screened for actin accumulation and pedestal formation in, for example, cultured HeLa epithelial cells.

5 EPEC and EHEC invasion is another cell culture phenotype that is readily measured, and gives an indication of interactions with cultured epithelial cells and ability to alter host cytoskeleton (type III mutants do not invade, nor do strains lacking Tir and intimin). The invasion levels of various candidate compounds may be compared in wt and type III mutant A/E pathogen, for example, WT and TTSS mutant  
10 EHEC in HeLa cells, using a gentamicin protection assay.

In addition, the ability of the candidate compounds to block cultured macrophage phagocytosis can be tested, as EPEC and EHEC inhibit phagocytosis in cultured macrophages by inhibiting host PI 3-kinase activity in a type III dependent manner (Celli, J., M. Olivier, and B. B. Finlay. 2001. Enteropathogenic Escherichia  
15 coli mediates antiphagocytosis through the inhibition of PI 3-kinase-dependent pathways. *Embo J* 20:1245-58). If any candidate compounds are unable to inhibit phagocytosis, a secondary assay of PI-3 kinase inhibition can be performed.

Effects on polarized epithelial monolayers.

20 Junctional integrity plays a key role in diarrhea. In addition to pedestal formation, A/E pathogens cause other LEE type III effects on polarized epithelial cells, including loss of microvilli (microvilli effacement) and loss of transmonolayer electrical resistance, a measure of tight junctions. Using polarized human intestinal monolayers of Caco-2 cells, high resolution scanning electron microscopy may be  
25 performed on monolayers infected with WT A/E pathogen (e.g, WT EHEC), TTSS mutant A/E pathogen, e.g, EHEC *escN*, and each of the candidate compounds. Monolayers can be infected for various times, washed, and processed for SEM using standard techniques (66) and screened for loss of electrical resistance after infecting polarized Caco-2 cells.

30

Effects on innate immunity and inflammation



A rapidly emerging theme among pathogens is the ability to inhibit innate immunity and inflammatory responses. Such effects have been reported for A/E pathogens such as EHEC and EPEC, and these assays may be used to examine candidate compounds in WT and TTSS mutant A/E pathogen strains. For example, EHEC causes inhibition of NF- $\kappa$ B, resulting in suppression of several cytokines such as IL-8, IL-6, and IL-1 $\alpha$  in HeLa cells (80), and this process requires the LEE TTSS. Candidate compounds may be assayed for inhibition of these factors following, for example, infection of HeLa cells, using standard methods such as RT-PCR (real time PCR), and commercially available ELISA assays.

#### Functional studies based on localization information

In addition to phenotypic assays, candidate compounds may be assayed depending on their localization with a host cell. For example, if a candidate compound localizes to the Golgi, it can be assayed to determine if it affects Golgi function, including biochemical studies examining glycosylation, and functional Golgi assays in yeast expressing the candidate compounds. If the candidate compound localizes to mitochondria, assays on apoptosis and other mitochondrial functions can be utilized. If the candidate compound targets to the endoplasmic reticulum, protein synthesis and secretion assays can be designed. If nuclear targeting occurs, transcriptional studies may be conducted.

#### Role in virulence

Competitive indices (CI) have been used extensively to determine the role of minor virulence factors, as well as whether two virulence factors belong to the same virulence "pathway" (63). Briefly, two strains, marked with different antibiotic resistances, are coinfecting into an animal, and following appropriate incubation times, bacteria are harvested and a ratio of the two strains determined. A value of 1 indicates equal virulence. If identified compounds have an effect on virulence, their CI compared to WT may be determined. CI may also be used to determine which virulence pathways the candidate compounds belong to. For example, CIs may be determined by comparing mutants of two virulence factors, in addition to comparing each one to WT. When comparing the single mutants and to a double mutant, a CI ratio of 1

indicates they belong to the same general virulence pathway, while anything other than 1 indicates they are on different virulence “paths”.

#### Microscopy studies

5 Microscopy techniques may be used to characterize A/E pathogen disease, including transmission electron microscopy (TEM) and scanning electron microscopy (SEM) to examine lymphoid follicles in distal ileal Peyer's patches from REPEC infected rabbits to confirm A/E lesion formation (63), confocal microscopy to show delivery into murine villi, and histological analysis of the disease process in infected  
10 mice.

These techniques may be used to assay candidate compounds in suitable animal models, for example, mice infected with various *Citrobacter* strains carrying mutations in the candidate sequences. For each candidate compounds, a comprehensive study may be undertaken to follow the disease progression (or lack of)  
15 in this system. In addition, the level of colonization of these mutants on intestinal surfaces may be determined. Antibiotic marked strains may be used to infect animals, followed by harvesting of intestinal tissue. Tissue may be homogenized and bacteria quantitated by plate counting on selective plates.

A major feature of A/E pathogenic infection, e.g., *Citrobacter* infection, is  
20 extensive inflammation. The cellular events of inflammation may be followed by confocal microscopy for various mutants in candidate compounds. By labeling tissues with antibodies or lectins followed by confocal microscopy, the inflammatory cells that are recruited to the site of infection by the mutants may be defined, compared to the parental strain. Antibodies to several innate response factors are  
25 available and may also be used to analyze the mutant phenotypes during infection, examining innate response factors and cells such as macrophages, neutrophils, iNOS production, dendritic cells, etc.

#### Histological studies

30 Histological studies of stained tissue may be conducted. For example, hematoxylin and eosin-stained ileal sections of rabbits infected with REPEC and strains with deletions in candidate compounds may be studied to compare the

inflammation and tissue damage and characterize A/E pathogen infections (58). Similar staining may be done with *Citrobacter* strains lacking candidate compounds in mice. Several other histological stains are available that may further define the inflammation associated with *Citrobacter* and isogenic mutants, including Giemsa and Toluidine Blue O (for general morphology), Periodic Acid-Schiff (stains carbohydrates, allowing examination of the intestinal mucus layer and goblet cells), Gram stain, chloroacetate esterase (an inflammatory cell stain), and a caspase assay (for apoptosis). Immunohistochemistry allows utilization of antibodies directed against bacterial and mammalian cell antigens.

#### Antibodies

The compounds of the invention can be used to prepare antibodies to the polypeptides of the invention, using standard techniques of preparation (45), or known to those skilled in the art.

For example, a coding sequence for a polypeptide of the invention may be purified to the degree necessary for immunization of rabbits. To attempt to minimize the potential problems of low affinity or specificity of antisera, two or three polypeptide constructs may be generated for each protein, and each construct is injected into at least two rabbits. Antisera may be raised by injections in a series, preferably including at least three booster injections. Primary immunizations may be carried out with Freund's complete adjuvant and subsequent immunizations with Freund's incomplete adjuvant. Antibody titres may be monitored by Western blot and immunoprecipitation analyses using the purified protein. Immune sera may be affinity purified using CNBr-Sepharose-coupled protein. Antiserum specificity may be determined using a panel of unrelated proteins. Alternatively or additionally, peptides corresponding to relatively unique immunogenic regions of a polypeptide of the invention may be generated and coupled to keyhole limpet hemocyanin (KLH) through an introduced C-terminal lysine. Antiserum to each of these peptides may be affinity purified on peptides conjugated to BSA, and specificity tested in ELISA and Western blots using peptide conjugates and by Western blot and immunoprecipitation.

Alternatively, monoclonal antibodies which specifically bind any one of the polypeptides of the invention are prepared according to standard hybridoma

technology (91, 90, 89, 78). Once produced., monoclonal antibodies may also be tested for specific recognition by Western blot or immunoprecipitation. Antibodies which specifically bind the polypeptide of the invention are considered to be useful; such antibodies may be used., e.g., in an immunoassay. Alternatively monoclonal antibodies may be prepared using the polypeptide of the invention described above and a phage display library (112).

In some embodiments, antibodies may be produced using polypeptide fragments that appear likely to be immunogenic, by criteria such as high frequency of charged-residues. Antibodies can be tailored to minimise adverse host immune response by, for example, using chimeric antibodies contain an antigen binding domain from one species and the Fc portion from another species, or by using antibodies made from hybridomas of the appropriate species.

In some embodiments, antibodies against any of the polypeptides described herein may be employed to treat or prevent infection by an A/E pathogen.

#### Animal Models

Compounds can be rapidly screened in various animal models of A/E pathogen infection.

The *Citrobacter* murine infection model is a naturally occurring disease model, and the adult bovine EHEC shedding model, a natural non-disease carriage model (cattle are not sick, yet EHEC is not part of the normal flora). For the *Citrobacter* model, mutants can be screened for virulence in mice as described herein. Knock out (KO)/mutant mice may be used to study the role of candidate sequences in infection. Several KO mouse lines have been developed, including defining the role of iNOS (20), T and B cells (106), Tlr-4 and establishing a range of host susceptibility (54), as well as Nck.

For the bovine model, the EHEC mutants can be screened in yearling cattle (see, for example, PCT Publication No. WO 02/053181). Briefly,  $10^8$  CFU of mutant or WT O157 are delivered to cattle via oral-gastric intubation. 14 days post-inoculation fecal shedding is monitored by selective plating, and colonies verified by mutliplex PCR, shedding levels, and histological and microscopic analyses of the perianal region where EHEC concentrates (97). Another model is the bovine intestinal loop model in which intestinal loops are injected with EHEC and at various

times examined histologically and microscopically, as well as quantitating adherent bacteria by plating.

A natural rabbit infection model of RDEC-1 infection may be conducted as follows: Overnight bacterial cultures are collected by centrifugation and resuspended in one ml of phosphate-buffered saline. New Zealand white rabbits (weight 1.0 to 1.6 kg) are fasted overnight, then five ml of 2.5% sterile sodium bicarbonate and one ml of RDEC- 1 or candidate sequence mutant strains ( $2 \times 10^{10}$ ) are inoculated into the stomach using orogastric tubes. The same dosage of bacteria is inoculated into each rabbit the following day. Each rabbit is weighed daily and fecal shedding of bacteria is collected by rectal swabs and from stool pellets. Rectal swabs are rolled over one half of the surface of MacConkey plates containing nalidixic acid. Five stool pellets or same amount of liquid stool are collected from each rabbit and resuspended in three ml phosphate-buffered saline and 0.1 ml of each stool suspension is plated onto MacConkey plate containing nalidixic acid. The growth of nalidixic resistant colonies is scored as follows: 0, no growth; 1, widely spaced colonies; 2, closely spaced colonies; 3, confluent growth of colonies. Tissues are excised immediately following sacrifice by intravenous injection of ketamine and overdosing with sodium phenobarbital. The amount of bacterial colonization in intestinal tissues is assayed as follows: The intestinal segments (10 cm), except cecum, are doubly ligated at their proximal and distal ends, and dissected between the double ligated parts, then flushed with 10 ml of ice-cold phosphate-buffered saline. One gram of viscous contents from the cecum is added to 9 ml phosphate-buffered saline. The resulting phosphate-buffered saline suspensions are diluted and plated on MacConkey plates containing nalidixic acid. Tissue samples are excised using a 9 mm diameter cork punch, washed three times with phosphate-buffered saline, added to two ml of ice-cold phosphate-buffered saline, and homogenized with a homogenizer, then serial diluted samples are plated onto MacConkey plates. The numbers of bacteria adherent to each tissue per square centimeter are calculated as follows:  $\text{CFU/cm}^2 = \frac{\text{the bacterial number/plate} \times \text{dilution factor} \times 2 \text{ ml}}{0.452}$ .

Therapeutics and Diagnostics

The polypeptide and nucleic acid molecules described herein may be used as therapeutics, for example, for the preparation of vaccine or therapeutic compositions, or the construction of A/E pathogens that are attenuated in virulence. Such A/E pathogens may be constructed as described herein by, for example, designing primers based on the nucleic acid sequences described herein, and using a *sacB* gene-based allelic exchange technique (29). The polypeptides and nucleic acid molecules may be used alone or in combination with each other or other suitable molecules, such as EspA, EspB, EspD, EspP, Tir, Shiga toxin 1, Shiga toxin 2, or intimin molecules.

In some embodiments, the nucleic acid molecules described herein may be used in antisense techniques. By “antisense,” as used herein in reference to nucleic acids, is meant a nucleic acid sequence that is complementary to the coding strand of a nucleic acid molecule, for example, a gene, such as a *nleA*, *nleB*, *nleC*, *nleD*, *nleE*, or *nleF* gene, or that is complementary to a nucleotide sequence substantially identical to the sequence of any one of SEQ ID NOs: 1-21 or 60-72 or a fragment or variant thereof. In some embodiments, an antisense nucleic acid molecule is one which is capable of lowering the level of polypeptide encoded by the complementary gene when both are expressed in a cell. In some embodiments, the polypeptide level is lowered by any integer from at least 10% to at least 25%, or by any integer from at least 25% to at least 50%, or by any integer from at least 50 % to at least 75%, or by any integer from at least 75% to 100%, as compared to the polypeptide level in a cell expressing only the gene, and not the complementary antisense nucleic acid molecule.

In some embodiments, expression of a gene or coding or non-coding region of interest may be inhibited or prevented using RNA interference (RNAi) technology, a type of post-transcriptional gene silencing. RNAi may be used to create a functional “knockout”, i.e. a system in which the expression of a gene or coding or non-coding region of interest is reduced, resulting in an overall reduction of the encoded product. As such, RNAi may be performed to target a nucleic acid of interest or fragment or variant thereof, to in turn reduce its expression and the level of activity of the product which it encodes. Such a system may be used for functional studies of the product, as well as to treat infection by an A/E pathogen. RNAi is described in for example published US patent applications 20020173478 (Gewirtz; published November 21,

2002) and 20020132788 (Lewis *et al.*; published November 7, 2002)(79, 67).

Reagents and kits for performing RNAi are available commercially from for example Ambion Inc. (Austin, TX, USA) and New England Biolabs Inc. (Beverly, MA, USA).

The initial agent for RNAi in some systems is thought to be dsRNA molecule  
5 corresponding to a target nucleic acid. The dsRNA is then thought to be cleaved into short interfering RNAs (siRNAs) which are 21-23 nucleotides in length (19-21 bp duplexes, each with 2 nucleotide 3' overhangs). The enzyme thought to effect this first cleavage step has been referred to as "Dicer" and is categorized as a member of the Rnase III family of dsRNA-specific ribonucleases. Alternatively, RNAi may be  
10 effected via directly introducing into the cell, or generating within the cell by introducing into the cell a suitable precursor (e.g. vector, etc.) of such an siRNA or siRNA-like molecule. An siRNA may then associate with other intracellular components to form an RNA-induced silencing complex (RISC). The RISC thus formed may subsequently target a transcript of interest via base-pairing interactions  
15 between its siRNA component and the target transcript by virtue of homology, resulting in the cleavage of the target transcript approximately 12 nucleotides from the 3' end of the siRNA. Thus the target mRNA is cleaved and the level of protein product it encodes is reduced.

RNAi may be effected by the introduction of suitable *in vitro* synthesized  
20 siRNA or siRNA-like molecules into cells. RNAi may for example be performed using chemically-synthesized RNA (64), for which suitable RNA molecules may chemically synthesized using known methods. Alternatively, suitable expression vectors may be used to transcribe such RNA either *in vitro* or *in vivo*. *In vitro* transcription of sense and antisense strands (encoded by sequences present on the  
25 same vector or on separate vectors) may be effected using for example T7 RNA polymerase, in which case the vector may comprise a suitable coding sequence operably-linked to a T7 promoter. The *in vitro*-transcribed RNA may in embodiments be processed (e.g. using *E. coli* RNase III) *in vitro* to a size conducive to RNAi. The sense and antisense transcripts combined to form an RNA duplex which is introduced  
30 into a target cell of interest. Other vectors may be used, which express small hairpin RNAs (shRNAs) which can be processed into siRNA-like molecules. Various vector-based methods are known in the art (65, 93, 95, 98, 99, 105, 109). Various methods

for introducing such vectors into cells, either *in vitro* or *in vivo* (e.g. gene therapy) are known in the art.

Accordingly, in an embodiment expression of a polypeptide including an amino acid sequence substantially identical to the sequence of any one of SEQ ID  
5 NOs: 22 through 43 may be inhibited by introducing into or generating within a cell an siRNA or siRNA-like molecule corresponding to a nucleic acid molecule encoding the polypeptide or fragment thereof, or to an nucleic acid homologous thereto. In various embodiments such a method may entail the direct administration of the siRNA or siRNA-like molecule into a cell, or use of the vector-based methods  
10 described above. In an embodiment, the siRNA or siRNA-like molecule is less than about 30 nucleotides in length. In a further embodiment, the siRNA or siRNA-like molecules are about 21-23 nucleotides in length. In an embodiment, siRNA or siRNA-like molecules comprise and 19-21 bp duplex portion, each strand having a 2 nucleotide 3' overhang. In embodiments, the siRNA or siRNA-like molecule is  
15 substantially identical to a nucleic acid encoding the polypeptide or a fragment or variant (or a fragment of a variant) thereof. Such a variant is capable of encoding a protein having the activity of a polypeptide encoded by SEQ ID NOs: 22-43. In embodiments, the sense strand of the siRNA or siRNA-like molecule is substantially identical to SEQ ID NOs: 1-21 or a fragment thereof (RNA having U in place of T  
20 residues of the DNA sequence).

In some embodiments, antibodies raised against the polypeptides of the invention may be used as therapy against infection by an A/E pathogen.

In some embodiments, the polypeptide and nucleic acid molecules of the invention may be used to detect the presence of an A/E pathogen in a sample. The  
25 nucleic acid molecules may be used to design probes or primers that could, for example, hybridize to the DNA of an A/E pathogen in a sample, or could be used to amplify the DNA of an A/E pathogen in a sample using, for example, polymerase chain reaction techniques. The polypeptides could be used for example to raise antibodies that specifically bind to a polypeptide expressed by an A/E pathogen. Such  
30 probes or primers or antibodies may be detectably labelled. By "detectably labelled" is meant any means for marking and identifying the presence of a molecule, e.g., an oligonucleotide probe or primer, a gene or fragment thereof, or a cDNA molecule.



Methods for detectably-labelling a molecule are well known in the art and include, without limitation, radioactive labelling (e.g., with an isotope such as  $^{32}\text{P}$  or  $^{35}\text{S}$ ) and nonradioactive labelling such as, enzymatic labelling (for example, using horseradish peroxidase or alkaline phosphatase), chemiluminescent labeling, fluorescent labeling (for example, using fluorescein), bioluminescent labeling, or antibody detection of a ligand attached to the probe. Also included in this definition is a molecule that is detectably labeled by an indirect means, for example, a molecule that is bound with a first moiety (such as biotin) that is, in turn, bound to a second moiety that may be observed or assayed (such as fluorescein-labeled streptavidin). Labels also include digoxigenin, luciferases, and aequorin.

#### Pharmaceutical & Veterinary Compositions, Dosages, And Administration

Compounds include the polypeptide and nucleic acid molecules described herein, as well as compounds identified using the methods of the invention.

Compounds according to the invention can be provided alone or in combination with other compounds (for example, nucleic acid molecules, small molecules, polypeptides, peptides, or peptide analogues), in the presence of a liposome, an adjuvant, or any pharmaceutically acceptable carrier, in a form suitable for administration to mammals, for example, humans, cattle, sheep, etc. If desired, treatment with a compound according to the invention may be combined with more traditional and existing therapies for an A/E pathogen infection

Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer the compounds to subjects infected by an A/E pathogen. Any appropriate route of administration may be employed, for example, parenteral, intravenous, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol, or oral administration. Formulations may be in the form of liquid solutions or suspensions; tablets or capsules; powders, nasal drops, or aerosols.

Methods are well known in the art for making formulations (57). Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of

vegetable origin, or hydrogenated naphthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds. Other potentially useful parenteral delivery systems for modulatory compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel. For therapeutic or prophylactic compositions, the compounds are administered to an individual in an amount sufficient to stop or slow an A/E pathogen infection.

An "effective amount" of a compound according to the invention includes a therapeutically effective amount or a prophylactically effective amount. A "therapeutically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as reduction of colonization by or shedding of an A/E pathogen. A therapeutically effective amount of a compound may vary according to factors such as the disease state, age, sex, and weight of the subject, and the ability of the compound to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also one in which any toxic or detrimental effects of the compound are outweighed by the therapeutically beneficial effects. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as prevention of colonization by an A/E pathogen. Typically, a prophylactic dose is used in subjects prior to or at an earlier stage of disease, so that a prophylactically effective amount may be less than a therapeutically effective amount. A preferred range for therapeutically or prophylactically effective amounts of a compound may be any integer from 0.1 nM-0.1M, 0.1 nM-0.05M, 0.05 nM-15 $\mu$ M or 0.01 nM-10 $\mu$ M.

It is to be noted that dosage values may vary with the severity of the condition to be alleviated. For any particular subject, specific dosage regimens may be adjusted over time according to the individual need and the professional judgement of the

person administering or supervising the administration of the compositions. Dosage ranges set forth herein are exemplary only and do not limit the dosage ranges that may be selected by medical practitioners. The amount of active compound in the composition may vary according to factors such as the disease state, age, sex, and weight of the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It may be advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.

In the case of vaccine formulations, an effective amount of a compound of the invention can be provided, alone or in combination with other compounds, and with one or more of an immunological adjuvant to induce an immune response. Adjuvants according to the invention may include emulsifiers, muramyl dipeptides, avridine, aqueous adjuvants such as aluminum hydroxide, chitosan-based adjuvants, saponins, oils, Amphigen®, LPS, bacterial cell wall extracts, bacterial DNA, bacterial complexes, synthetic oligonucleotides and combinations thereof (100). The adjuvant may include a *Mycobacterium phlei* (*M. phlei*) cell wall extract (MCWE) (U. S. Patent No. 4,744,984), a *M. phlei* DNA (M-DNA), or a Mycobacterial cell wall complex (MCC). Emulsifiers include natural and synthetic emulsifying agents. Synthetic emulsifying agents include anionic agents (e.g., potassium, sodium and ammonium salts of lauric and oleic acid, the calcium, magnesium and aluminum salts of fatty acids, i. e., metallic soaps, and organic sulfonates, such as sodium lauryl sulfate), cationic agents (e.g., cetyltrimethylammonium bromide), and nonionic agents (e.g., glyceryl esters such as glyceryl monostearate, polyoxyethylene glycol esters and ethers, and the sorbitan fatty acid esters such as sorbitan monopalmitate and their polyoxyethylene derivatives, e. g., polyoxyethylene sorbitan monopalmitate). Natural emulsifying agents include acacia, gelatin, lecithin and cholesterol. Other suitable adjuvants include an oil, such as a single oil, a mixture of oils, an oil-in-water emulsion (e.g., EMULSIGEN™, EMULSIGEN PLUS™ or VSA3), or a non-oil-in-water emulsion (e.g., an oil emulsion, a water-in-oil emulsion, or a water-in-oil-in-water emulsion). The oil may be a mineral oil, a vegetable oil, or an animal oil.

Suitable animal oils include, for example, cod liver oil, halibut oil, menhaden oil, orange roughy oil or shark liver oil, all of which are available commercially. Suitable vegetable oils, include, without limitation, canola oil, almond oil, cottonseed oil, corn oil, olive oil, peanut oil, safflower oil, sesame oil, or soybean oil. Alternatively, a number of aliphatic nitrogenous bases may be used as adjuvants with the vaccine formulations. For example, known immunologic adjuvants include amines, quaternary ammonium compounds, guanidines, benzamidines and thiouroniums (75). Specific adjuvant compounds include dimethyldioctadecyl ammonium bromide (DDA) (U. S. Patent No. 5,951,988)(88, 59, 85, 68, 84, 82, 83) and N, N-dioctadecyl-N, N-bis (2 hydroxyethyl) propanediamine ("avridine") (U. S. Patent No. 4,310,550, U. S. Patent No. 5,151,267)(62). An adjuvant according to the invention may for example include a mineral oil and dimethyldioctadecylammonium bromide.

Vaccine compositions may be prepared using standard techniques including, but not limited to, mixing, sonication and microfluidation. The adjuvant may be comprise about 10 to 50% (v/v) of the vaccine, or about 20 to 40% (v/v) or about 20 to 30% or 35% (v/v), or any value within these ranges. The compound may also be linked with a carrier molecule, such as bovine serum albumin or keyhole limpet hemocyanin to enhance immunogenicity.

In general, compounds of the invention should be used without causing substantial toxicity. Toxicity of the compounds of the invention can be determined using standard techniques, for example, by testing in cell cultures or experimental animals and determining the therapeutic index, i.e., the ratio between the LD50 (the dose lethal to 50% of the population) and the LD100 (the dose lethal to 100% of the population). In some circumstances however, such as in severe disease conditions, it may be necessary to administer substantial excesses of the compositions.

The following examples are intended to illustrate embodiments of the invention, and should not be construed as limitations on the scope of the invention.

#### Example 1

Generation of mutants

Bacterial strains used are as follows: EHEC O157:H7 strain 86//24 (32), EHEC EDL933 (wildtype *E. coli* O127:H7 isolate; 3); EHEC *escN*- (47), wild type EPEC E2348/69 (wildtype *E. coli* O127:H6 isolate; 50), *C. rodentium* DBS100 (ATCC 51459; 53), REPEC 0103:K-H2 85/150 (52), *E. coli* HB101.

Plasmids used were as follows:

Plasmid	Description and Relevant Phenotype	Reference
pRE118	<i>sacB</i> -based suicide vector for allelic exchange, Kan <sup>r</sup>	4
pKD46	Plasmid expression $\lambda$ red recombinase, AMP <sup>r</sup>	5
pACYC184	Cloning Vector, CM <sup>r</sup> Tet <sup>r</sup>	NEB
pCR2.1-TOPO	PCR cloning vector, Amp <sup>r</sup> Kan <sup>r</sup>	Invitrogen
pTOPO-2HA	pCR2.1-TOPO based, <i>Plac</i> -driven expression cassette for C-terminal 2HA tagging, Amp <sup>r</sup> Kan <sup>r</sup>	
pCRespG-2HA/BgIII	pACYC184 based, <i>Citrobacter</i> <i>espG</i> promoter-driven expression cassette for C-terminal 2HA tagging Cm <sup>r</sup>	
pCR1er	<i>C. rodentium</i> <i>ler</i> in pCR2.1-TOPO	
pCRorf11	<i>C. rodentium</i> <i>orf11/grlA</i> in pCR2.1-TOPO	
pEHorf11	EHEC <i>orf11/grlA</i> in pCR2.1-TOPO	
pEPorf11	EPEC <i>orf11/grlA</i> in pCR2.1-TOPO	
pKK232-8	pBR322 derivative containing a promoterless <i>cat</i> gene	Pharmacia
pLEE1-CAT	pKK232-8 derivative carrying <i>C. rodentium</i> <i>LEE1</i> ( <i>Ler</i> )- <i>cat</i> transcriptional fusion from nucleotides – 162 to +216.	
pLEE5-CAT	pKK232-8 derivative carrying <i>C. rodentium</i> <i>LEE5</i> ( <i>Tir</i> )- <i>cat</i> transcriptional fusion from nucleotides – 262 to +201.	

For PCR and inverse PCR, the proof-reading ELONGASE Amplification System (GIBCO BRL/Life Technologies) was routinely used to minimize PCR error rate. PCR products were cloned using the TOPO TA Cloning Kit from Invitrogen

with either pCR2. 1-TOPO or pCRII-TOPO. DNA sequence was determined using the Taq Dye- terminator method and an automated 373A DNA Sequencer (Applied Biosystems). For routine cloning, transformation, and infections, bacteria were grown in Luria-Bertani (LB) agar or LB broth supplemented with appropriate antibiotics at 37°C. Various antibiotics were used at the following concentrations, ampicillin 100 µg/ml, carbenicillin 100 µg/ml, kanamycin 50 µg/ml, and chloramphenicol 30 µg/ml. Growth in Dullbecco's modified Eagle's medium (DMEM) was used for induction of LEE gene expression and type III protein secretion.

The *sacB* gene-based allelic exchange (14) and the lambda Red recombinase system (17), were used to generate the mutants. In general, 75% or more of the internal portion of each gene was deleted to ensure the disruption of the function of the gene. The *ler* gene was mutated by the lambda red recombinase method and the *ler*, *orf11/grlA*, and *cesT* genes were mutated by the *sacB* gene-based allelic exchange method. The double mutant of *ler/orf11* was also generated using the *sacB* -based method. The generation of the *tir* and *escD* mutants was described elsewhere (20, 56). The mutants were in-frame deletion mutants, with the introduction of a restriction enzyme site (either *Nhe* I, *Bam* HI, or *Sal* I) at the site of deletion as follows:

LEE mutant name	Protein length (aa)	Codons deleted (from # to #)	Features introduced at the deletion site	Deletion methods employed
$\Delta ler$	129	23-97 or 9-122	<i>Nhe</i> I or <i>aphT</i> cassette	SacB or Lambda Red
$\Delta orf11/grlA$	135	23-115	<i>Nhe</i> I	SacB
$\Delta cesT$	156	25-147	<i>Nhe</i> I	SacB

These mutants were verified by multiple PCR reactions. Complementation was tested for the  $\Delta tir$ ,  $\Delta ler$ , and  $\Delta orf11$  mutants by supplying the respective gene on a plasmid. All of these mutants can be complemented, confirming that the mutations generated by both allelic exchange methods did not affect the function of downstream genes and are therefore non-polar.

To make EHEC-pNleA-HA, the coding region of *nleA* was amplified using the proof-reading ELONGASE Amplification System (Invitrogen) and the following

primers: Z6024F:

5'AGATCTGAAGGAGATATTATGAACATTCAACCGACCATAC (SEQ ID NO:44); Z6024R: 5'CTCGAGGACTCTTGTTCCTTCGATTATATCAAAG (SEQ ID NO:45). PCR products were cloned using the TOPO TA Cloning Kit (Invitrogen) and the DNA sequence was verified using the Taq Dye-terminator method and an automated 373A DNA Sequencer (Applied Biosystems). The product was then subcloned into pCRespG-2HA/BglII, a pACYC-derived plasmid engineered to drive protein expression from a *C. rodentium* EspG promoter and to add two influenza hemagglutinin (HA) to the C-terminus of the expressed protein. The plasmid constructs were then introduced into wildtype EHEC and EHEC *escN*- by electroporation.

A deletion mutant in *nleA* in a nalidixic acid resistant strain of EHEC was created by *sacB* gene-based allelic exchange (29). Two DNA fragments that flank *nleA* were PCR amplified using EHEC chromosomal DNA as template.

Fragment A was PCR amplified using primer NT10 5'CCGGTACCTCTAACCATTGACGCACTCG (SEQ ID NO:46) and primer NT11 5'AACCTGCAGAACTAGGTATCTCTAATGCC (SEQ ID NO:47) to generate a 1.3 kb product.

Fragment B was amplified using primer NT12 5'AACCTGCAGCTGACTATCCTCGTATATGG (SEQ ID NO:48) and primer NT13 5'CCGAGCTCAGGTAATGAGACTGTCAGC (SEQ ID NO:49) to generate a 1.3 kb product.

Fragments A and B were then digested with *Pst*I for 1 hr and then the enzyme was heat inactivated for 20 minutes at 65°C. Approximately 50 ng of each digested fragment was ligated with T4 DNA ligase for 1 hr at room temperature. The ligation reaction was diluted 1/10 and 1 µl was added to a PCR using primers NT10 and NT13. The resulting 2.3kb PCR product was then digested with *Sac*I and *Kpn*I, ligated to the corresponding sites of pRE112 (14) and transformed into DH5αpir to generate pNT225. pNT225 was transformed into the conjugative strain SM10λpir which served as the donor strain in a conjugation with wild type EHEC. Nalidixic acid and chloramphenicol resistant exoconjugants were selected on LB agar. The exoconjugants were then plated onto LB agar containing 5% (w/v) sucrose, and no

NaCl. The resulting colonies were then screened for sensitivity to chloramphenicol, followed by PCR to identify isolates with the *nleA* deletion and loss of plasmid sequences. A *nleA* deletion mutant was then isolated and used for further work. A *C. rodentium* *nleA* mutant was generated using PCR was used to create, in pRE118 (14), a suicide vector bearing an internal deletion of *nleA*.

The following primers were used: del1F:

5'GGTACCACCACACAGAATAATC (SEQ ID NO:50); del1R:

5'CGCTAGCCTATATACTGCTGTTGGTT (SEQ ID NO:51); del2F:

5'GCTAGCTGACAGGCAACTCTTGGACTGG (SEQ ID NO:52); del2R:

5'GAGCTCAACATAATTTGATGGATTATGAT (SEQ ID NO:53). The resulting plasmid was introduced into *C. rodentium* by electroporation to create a antibiotic-resistant merodiploid strain. Loss of plasmid sequences through a second recombination event was selected for as described above. Antibiotic-sensitive, sucrose-resistant colonies were verified for the proper recombination event by PCR utilizing primers flanking the deleted region. The absence of NleA was verified by Western blotting whole cell lysates with polyclonal anti-NleA antiserum.

#### Assaying total and secreted proteins/proteomics

Secreted proteins were prepared as previously described (51).

*C. rodentium* strains were grown overnight in a shaker in 4 ml of Luria broth (LB) at 37°C. The cultures were subcultured 1 to 50 into 4 ml of Dulbecco's modified Eagle's medium (DMEM) which was pre-incubated in a tissue culture incubator (with 5% CO<sub>2</sub>) overnight, and grown standing for 6 hours in the same incubator to induce LEE gene expression. The cultures were centrifuged twice at 13,000 rpm for 10 min. to remove the bacteria, and the supernatant was precipitated with 10% trichloroacetic acid (TCA) to concentrate proteins secreted into the culture media. The bacterial pellet was dissolved in 2X SDS-PAGE buffer and designated as total bacterial proteins. The secreted proteins precipitated from the supernatant were also dissolved in 2X SDS-PAGE buffer and the residual TCA was neutralized with 1 µl of saturated Tris. The volumes of buffer used to re-suspend the bacterial pellet as well as the secreted proteins were normalized to the OD600 of the cultures to ensure equal loading of the samples. The secreted proteins were analyzed in 12% or 17% SDS-



PAGE, and stained with 0.1% Coomassie Blue G250. For Western blot analysis, total or secreted proteins were separated in 10% SDS-PAGE, and transferred onto nitrocellulose membrane (Bio-Rad). The antibodies used were rat polyclonal antibodies against the His-tagged *Citrobacter* Tir, and mouse monoclonal antibody against EPEC EspB. Standard ECL Western blotting protocols were followed (Amersham Life Science).

Wildtype EHEC and EHEC CVD451 were grown overnight in LB medium. Cultures were then diluted 1:100 into M-9 minimal medium supplemented with 44 mM NaHCO<sub>3</sub>, 8 mM MgSO<sub>4</sub>, 0.4% glucose and 0.1% Casamino acids and grown standing at 37°C in 5% CO<sub>2</sub> to an OD<sub>600</sub> of 0.6 to 0.8.

Secreted proteins were harvested by centrifuging cultures at 8000g for 30 minutes, thus separating the supernatants from the pellets. Supernatants were filtered through 0.45 micron filters and the protein concentration determined by BCA assay (Sigma). Proteins were prepared for electrophoresis by precipitation with 1/9 volume 100% cold TCA, on ice for 45 to 120 min, followed by centrifugation at 17600g for 30 min. The pellets were rinsed in cold 100% acetone and solubilized in 1X Laemmli buffer (for 1-dimensional SDS-PAGE gels) or 2D sample buffer for 2D gels (8M urea, 2M thiourea, 4% CHAPS, 20 mM Tris, 0.002% bromophenol blue). For 2D gels, DTT was added to 6 mg/ml, and IPG buffer (pH 3-10: Amersham Biosciences) to 0.5% before loading. 18 cm Immobiline Dry Strips (pH 3-10: Amersham) were rehydrated in the sample overnight at 20°C. Samples were then focused at 15°C for 65,000 Vh. After focusing, strips were equilibrated in EB + 10 mg/ml DTT for 15 minutes, and then EB + 25 mg/ml Iodoacetamide for 15 minutes (EB is 50 mM Tris, 6M Urea, 30% glycerol, 2% SDS, pH8.8). Equilibrated strips were sealed onto the top of large format SDS-PAGE gels (12% or 14% acrylamide) using 0.5% agarose in SDS-PAGE running buffer + 0.002% bromophenol blue and the gels were run until the dye front ran off the gel.

Gels were stained with Sypro Ruby as per the manufacturers instructions (BioRad) and visualized on a UV lightbox or by MS/MS on a LCQ Deca Ion Trap Mass Spectrometer (Thermo Finnigan) equipped with a Nanoflow Liquid Chromatography system (LC Packings–Dionex). For gels visualized on a UV lightbox, spots of interest were excised manually. In-gel digestion of proteins was

performed on the Investigator ProGest Robot(Genomic Solutions, Ann Arbor, MI) as described (23). Samples of high protein abundance were analyzed by an LC-MS system consisting of a Nanoflow Liquid Chromatography system equipped with FAMOS Autosampler (LC Packings –Dionex, San Francisco, CA), and an LCQ Deca  
5 Ion Trap Mass Spectrometer (Thermo Finnigan, San Jose, CA)(24).

Reversed-phase PicoFrit Columns PFC7515-PP18-5 (New Objective, Woburn, MA, USA) were used for peptide separation and the column effluent was sprayed directly into the Mass Spectrometer. A flow rate of 200 nL/min was used and the total acquisition time was equal to 45 min per sample.

10 Low protein abundance samples were analyzed on an API QSTAR Pulsar Hybrid MS/MS Mass Spectrometer (Applied Biosystems/MDS SCIEX, Concord, Canada)(12) equipped with a Nanospray Ion Source (Proxeon, Odense, Denmark). Prior to the analysis, samples were purified and concentrated on ZipTips (Millipore, Billerica, MA). The API QSTAR Pulsar was also used for *de novo* peptide  
15 sequencing.

Spectra were searched against the NCBI (Bethesda, MD) DataBase with Mascot (Matrixscience) or Sonar (Proteometrics Canada Ltd.) search engines.

#### Construction of *cat* transcriptional fusions and CAT assay

20 PCR fragments carrying the promoters and all the upstream regulatory elements of *Citrobacter ler* (*LEE1*) and *tir* (*LEE5*) were digested with *Bam* HI and *Hind* III, and cloned into plasmid pKK232-8, which contains a promoterless *cat* gene. The positions spanned by the cloned fragments are as indicated herein. The CAT activity directed by these fusions in different *Citrobacter* strains was determined as  
25 described previously (21, 22). Samples were collected at different time points from bacterial cultures grow in DMEM as described above.

#### Sequence analysis and bioinformatics tools

DNA and protein sequence analysis and homology search by BLASTN,  
30 TBLASTN, and BLASTP were carried out using programs available from the NCBI website (<http://www.ncbi.nih.org/>). Databases used include those from the NCBI site, the Sanger Genome Centre (<http://www.sanger.ac.uk/Projects/Microbes>), and the

SwissProt (<http://www.expasy.org/sprot/>). The positions of the LEE PAI as well as the prophages in the EHEC genome were obtained from data generated by the IslandPath program (<http://www.pathogenomics.sfu.ca/islandpath/>)(13).

5           Southern blot analysis

Genomic DNA samples for Southern blot analysis were prepared using DNeasy Tissue kit (Qiagen). Probe was prepared by digesting pNleA-HA with *Sa*II and *Bg*II enzymes to obtain a 500bp fragment, which was labeled using BrightStar Psoralen-Biotin Nonisotopic Labeling Kit (Ambion).

10           Five micrograms of each genomic DNA sample were fully digested with 25 units of *Bam*HI, *Eco*RI, and *Pst*I overnight. The samples were resolved by electrophoresis on 1% agarose gel, and transferred overnight to BrightStar-Plus nylon membrane (Ambion) by passive, slightly alkaline downward elution. The DNA was cross-linked to the membrane by exposing the membrane to UV light for 2 min,  
15 followed by 30 min of baking at 80°C.

The membrane was prehybridized by washing it in 10 ml of ULTRAhyb Ultrasensitive Hybridization Buffer (Ambion) at 42°C for 30 min. Ten microliters of the prepared probe were then added to the prehybridized membrane in buffer and the probe was hybridized to the membrane overnight at 42°C. Membrane was washed 2  
20 times 5 min in low stringency wash buffer (Ambion) and 2 times 15 min in high stringency wash buffer (Ambion) at room temperature. The hybridized probe was detected using BrightStar BioDetect Nonisotopic Detection Kit (Ambion), followed by exposure to Kodak film.

25           Generation of anti-NleA antiserum

The coding portion of *nleA* was amplified from EHEC genomic DNA and cloned into a his-tagged expression vector (pET28a, Novagen) using following primers: 5'TTCCATATGAACATTCAACCGACC (SEQ ID NO:54) and 5'GGAATTCAATAATAGCTGCCATCC (SEQ ID NO:55). This plasmid was  
30 introduced into BL21 ( $\lambda$ DE3), grown to an optical density (A600) of 0.8 and induced with 0.5mM IPTG for 16 h at 20°C. His-tagged protein was purified on a Ni-NTA column as per the manufacturers' instructions (Qiagen). The NleA containing

fractions were pooled and thrombin was added (500:1) and the protein was dialysed overnight against 20mM tris pH 8. 2, 50mM NaCl. The next day the protein was loaded on a monoQ FPLC column and the column was developed with a linear gradient from 50 to 500 mM NaCl. NleA containing fractions were pooled. The protein was >90% pure after this step. Purified protein was used to immunize two male Sprague Dawley rats, 300µg protein/rat using Freund's complete adjuvant (Sigma), and the resulting antisera was affinity purified using the activated immunoaffinity support Affi-Gel 15 as per the manufacturer's instructions (BioRad). For immunofluorescence experiments, antiserum was further purified by absorption against acetone powders prepared from HeLa cells and from EHEC . NleA as described in (45). Specificity of antiserum was confirmed by Western blotting of cell extracts from wildtype EHEC and EHEC . NleA.

#### Immunoblot analysis

Samples for Western blot analysis were resolved by SDS-PAGE (9% to 12% polyacrylamide). Proteins were transferred to nitrocellulose and immunoblots were blocked in 5% nonfat dried milk (NFDM) in TBS, pH 7.2, containing 0.1% Tween 20 (TBST) overnight at 4°C, and then incubated with primary antibody in 1% NFDM TBST for 1 hr at room temperature (RT). Membranes were washed 6 times in TBST, and then incubated with a 1:5000 dilution of horseradish peroxidase-conjugated goat anti-mouse (H+L) antibody (Jackson ImmunoResearch Laboratories Inc. ) for 1 hr at RT. Membranes were then washed as described above. Antigen-antibody complexes were visualized with enhanced chemiluminescence detection kit (Amersham), followed by exposure to Kodak film (Perkin Elmer). The following primary antibodies were utilized: anti-HA.11 (Covance), anti-DnaK ( Stressgen), anti-EHEC Tir, anti-NleA (this study), anti-Calnexin (Stressgen), anti-Calreticulin (Affinity Bioreagents), anti-tubulin (Sigma).

#### Immunofluorescence

HeLa cells were grown on glass coverslips in 24 well tissue culture plates and infected for 6 hours with 1 ul (EHEC) of a standing overnight culture of OD ~0.4. At 6 hours post-infection, cells were washed 3 times in PBS containing Ca<sup>2+</sup> and Mg<sup>2+</sup>,

and fixed in 2.5% paraformaldehyde in PBS for 15 minutes at room temperature. Cells were permeabilized in 0.1% saponin in PBS, blocked in 5% goat serum or 5% BSA in PBS + 0.1% saponin, and incubated with the following primary antibodies diluted in blocking solution for 1 hour at room temperature: anti-EHEC Tir, 1:1000; 5 anti-*E. coli* O157 (Difco), 1:200; affinity-purified rat polyclonal anti-NleA (this study), 1:100; anti-mannosidase II (kindly provided by Dr. Marilyn Farquhar, UCSD), 1:1000. After 3 washes in PBS/saponin, cells were incubated in secondary antibodies (Alexa-488 or -568-conjugated anti-mouse, rabbit, rat (Molecular Probes) 1:400), for 30 minutes at room temperature, washed 3 times in PBS/saponin and once in PBS, 10 and mounted onto glass slides using mowiol + DABCO. For visualization of polymerized actin, Alexa-488-conjugated phalloidin (Molecular Probes) was included with the secondary antibodies at a 1:100 dilution. Where indicated, cells were incubated with 5 µg/ml brefeldin A (Boehringer Mannheim) for 30 minutes before fixation. Images were detected using a Zeiss Axioskop microscope, captured with an 15 Empix DVC1300 digital camera and analyzed using Northern Eclipse imaging software, or on a BioRad Radiance Plus confocal microscope using Lasersharpp software.

#### Fractionation of infected host cells

20 For each sample, two confluent 100 mm dishes of HeLa cells were infected with wildtype EHEC-pNleA-HA or EHEC*cscN*-pNleA-HA using an initial MOI of 1:10. At 6 hours post-infection, cells were washed three times with ice-cold PBS and subjected to biochemical fractionation as previously described (30, 49). Briefly, cells were resuspended in 300 µL homogenization buffer (3 mM imidazole, 250 mM 25 sucrose, 0.5 mM EDTA, pH 7.4) supplemented with COMPLETE protease inhibitor cocktail (Roche) and mechanically disrupted by passage through a 22-gauge needle. The homogenate was centrifuged at low speed (3000g) for 15 minutes at 4°C to pellet unbroken cells, bacteria, nuclei and cytoskeletal components (low speed pellet). The supernatant was subject to high speed ultracentrifugation (41,000g) for 20 minutes at 30 4°C in a TLS55 rotor in a TL100 centrifuge (Beckman) to separate host cell membranes (pellet) from cytoplasm (supernatant). The pellets were resuspended in 300 µL 1X laemmli buffer, and the supernatant was made up to 1X laemmli buffer

using a 5X stock. Equal volumes of all fractions were resolved by SDS-PAGE (9% polyacrylamide) and transferred to nitrocellulose and assayed by Western blot.

For extraction studies of membrane associated NleA, two 100 mm dishes of infected HeLa cells were fractionated as described above for each extraction condition. The high speed pellets (host membrane fraction) were resuspended in 300  $\mu$ L of one of the following extraction buffers: (i) 10 mM Tris, 5 mM  $MgCl_2$ , pH 7.4; (ii) 10 mM Tris, 5 mM  $MgCl_2$ , 1 M NaCl, pH 7.4; (iii) 0.2 M  $NaHCO_3$ , 5 mM  $MgCl_2$ , pH 11.4; (iv) 10 mM Tris, 5 mM  $MgCl_2$ , 1% Triton X-100 pH 7.4. Extraction was performed on ice by pipetting the samples up and down every 5 minutes for 30 minutes and the samples were recentrifuged at 100,000g for 30 minutes. The pellet (insoluble fraction) was resuspended in 300  $\mu$ L 1X laemmli buffer, the supernatant (soluble fraction) was precipitated in 10% trichloroacetic acid on ice for 30 minutes, washed in 100% acetone and resuspended in 300  $\mu$ L 1X laemmli buffer. Equal volumes were resolved by SDS-PAGE (9% polyacrylamide) and transferred to nitrocellulose and assayed by Western blot.

#### Infection analysis of *C. rodentium* in mice

5 week old C3H/HeJ mice (Jackson Laboratory) and outbred NIH Swiss mice (Harlan Sprague-Dawley) were housed in the animal facility at the University of British Columbia in direct accordance with guidelines drafted by the University of British Columbia's Animal Care Committee and the Canadian Council on the Use of Laboratory Animals. Wild-type *C. rodentium* and the *nleA* deletion mutant were grown in LB broth overnight in a shaker at 200 rpm and 100  $\mu$ L of the cultures was used to infect mice by oral gavage. Inoculum was titred by serial dilution and plating and was calculated to be  $4 \times 10^8$  cfu/mouse for both groups. For infection of the highly susceptible C3H/HeJ mice by *C. rodentium*, the survival of infected mice were assessed daily over the course of the infection. When any mouse became moribund, it was immediately sacrificed. For bacterial virulence assays using NIH Swiss mice, animals were sacrificed at day 10 post infection. To score colonic hyperplasia, the first 4 cm of the distal colon starting from the anal verge was collected and weighed after any fecal pellets were removed. To assay bacterial colonization, colonic tissues plus fecal pellets were homogenized in PBS using a Polytron Tissue Homogenizer,

and serially diluted before being plated on MacConkey agar (Difco Laboratories). Colonic tissue and fecal pellets were combined to determine the total bacterial burden in the mouse colon at the time of sacrifice. MacConkey agar is selective for Gram-negative bacteria, on which *C. rodentium* forms colonies with a highly distinctive and identifiable morphology not typical of *E. coli* (26). For histological analysis, the last 0.5 cm of the colon of infected mice was fixed in 10% neutral buffered formalin, processed, cut into 3  $\mu$ m sections and stained with hematoxylin and eosin. Histology analysis was done by the Morphological Services Laboratory at the Department of Pathology and Laboratory Medicine of the University of British Columbia.

10

## EXAMPLE 2

### Analysis of Regulation of LEE gene expression

To address which genes in the LEE regulate LEE gene expression in *C. rodentium*, we analyzed LEE mutants for expression of EspB and Tir, which are encoded by the *LEE4* and *LEE5 (Tir)* operons, respectively. Total cell lysates of bacteria grown in DMEM were analyzed by Western blot with anti-Tir and anti-EspB sera. Our results confirmed Ler's essential role in LEE expression, since no Tir and EspB were produced in  $\Delta$ ler. As expected,  $\Delta$ tir and  $\Delta$ espB did not produce Tir and EspB, respectively. No Tir was visible in  $\Delta$ cesT, consistent with CesT's role as the chaperone for Tir stability and secretion (18, 19). Surprisingly, another LEE-encoded protein, Orf11, was also required for the expression of Tir and EspB. Expression of Tir and EspB in  $\Delta$ orf11 was complemented by a plasmid carrying only *Citrobacter orf11* (Fig. 8). The *orf11* gene is highly conserved among A/E pathogens, and both EHEC and EPEC *orf11* complemented *Citrobacter*  $\Delta$ orf11 (Fig. 8), indicating that Orf11 is functionally equivalent in positive regulation of LEE gene expression in A/E pathogens.

20

25

30

Sequence analysis indicated that Orf11/GrlA shows 23% identity to CaiF, a transcriptional activator of the *cai* and *fix* operons of the *Enterobacteriaceae* (15), and 37% identity to the deduced amino acid sequence of a uncharacterized *Salmonella* product encoded by a gene located downstream of the *std* fimbrial operon (16) (Fig. 7). This *Salmonella* homologue is indicated as SGH (*Salmonella* GrlA Homologue) in

the figure. All three proteins contain a predicted helix-turn-helix motif characteristic of DNA binding proteins.

To address the hierarchy of Orf11 and Ler in regulating LEE gene expression, we created a double mutant of *ler* and *orf11* in *C. rodentium*. While Tir and EspB expression in  $\Delta ler \Delta orf11$  can be partially restored by expressing Ler *in trans*, similarly expressed Orf11 had no such effect (Fig. 8), suggesting that Orf11 acts upstream of Ler in the regulatory cascade. Primer extension analysis confirmed this regulatory hierarchy by showing that the *Citrobacter ler* promoter is similar to that of EPEC *ler* and its expression was reduced in  $\Delta orf11$ .

The role of Orf11 in regulating *ler* expression was further demonstrated by monitoring the activities of transcriptional fusions between the regulatory regions of the *LEE1 (Ler)* (pLEE1-CAT) or *LEE5 (Tir)* (pLEE5-CAT) operons and the *cat* reporter gene in *Citrobacter* WT,  $\Delta ler$ , and  $\Delta orf11$  strains grown in Dulbecco's Modified Essential Medium (DMEM) for 6 hrs. The activity of *LEE1-cat* fusion was decreased in  $\Delta orf11$ , and that of the *LEE5-cat* fusions was dramatically reduced in both  $\Delta ler$  and  $\Delta orf11$ . These results indicate that Orf11 is a novel positive regulator of the expression of Ler, which subsequently facilitates the expression of other LEE operons. Since Orf11 acts upstream of Ler in the regulatory cascade, it was named GrlA (for global regulator of LEE-activator).

### EXAMPLE 3

#### Identification of effectors secreted by LEE-encoded TTSS

A/E pathogens secrete several proteins into tissue culture or minimal media, but the secreted proteins are predominantly the translocators EspA, EspB, and EspD. Secreted proteins were concentrated by TCA precipitation from supernatants of bacterial cultures grown in DMEM and analyzed by 12% SDS-PAGE followed by Coomassie Blue staining. *C. rodentium* carrying a plasmid containing *orf11/grlA* secreted at least 300% more EspA, EspB, and EspD than the WT strain.

To define the effectors encoded by the *Citrobacter* LEE, we tagged various LEE-encoded proteins that are not involved in TTS and host cell adhesion with a double hemagglutinin (2HA) epitope at the carboxy terminus, and analyzed their secretion in WT and mutant *C. rodentium*. Only Tir, EspG, EspF, EspH, and Map



were secreted by the LEE-encoded TTSS in *C. rodentium*, suggesting that the LEE encodes only 5 effectors. A previously unrecognized 54 kDa protein (p54) was readily detected by Coomassie staining in a mutant that also had greatly enhanced secretion of Tir, suggesting that it represents a novel putative effector encoded outside the LEE.

5        To identify p54 and to determine whether additional effectors are encoded outside the LEE in *C. rodentium*, we took advantage of the ability of GrlA to increase LEE gene expression and/or type III secretion, and introduced the *grlA* plasmid into mutants that secreted effectors, but not translocators. Over-expression of GrlA greatly enhanced (by more than 400%) the secretion of Tir in these mutants, with no  
10        translocators being secreted. At least 6 additional secreted proteins were observed, indicating that the LEE-encoded TTSS secretes several additional non-LEE-encoded proteins.

      To identify these proteins, the secreted proteins were analyzed by 2-D gels. Since some of the LEE-encoded effectors (EspF, EspH, and Map) have predicted  
15        basic pI values, with EspF having an extreme pI of 11.00, the secreted proteins were first focused in Immobiline Dry Strips with both acidic (pH 3-10) and basic (pH 6-11) gradients, and then resolved in 12% and 14% SDS-PAGE, respectively. Gels were stained with Sypro Ruby, and selected protein spots were excised manually and analyzed by mass spectrometry and *de novo* peptide sequencing.

20        This analysis confirmed that the LEE-encoded Tir, EspF, EspG, EspH, and Map were type III secreted (Table 2).

Table 2. Effectors and Putative effectors secreted by the LEE-encoded TTSS in *C.*

<i>rodentium.</i>					
Serial number	Proposed name	Estimated MW	Estimated pI	Gene location	Homologues in EHEC and other pathogens
5	Tir	68	5.0	LEE	Tir, conserved in all A/E pathogens.
10	EspG	44	7.3	LEE	EspG, conserved in all A/E pathogens.
C1&C2	Map	23	9.0	LEE	Map, conserved in all A/E pathogens.
C3	EspF	31	11.0	LEE	EspF, conserved in all A/E pathogens.
C5&C6	EspH	21	8.7	LEE	EspH, conserved in all A/E pathogens.
7	NleA	54	5.8	Non-LEE	EHEC Z6024 in O-island 71 near prophage CP-933P.
12	NleB	39	5.9	Non-LEE	EHEC Z4328 in O-island 122, REPEC LEE-associated RorF, and <i>S. typhimurium</i> STMF1. Also has homology to Z0985 of O-island 36.
13	NleC	40	4.6	Non-LEE	EHEC Z0986 in O-island 36 near prophage CP-933K.
14	NleD	28	7.1	Non-LEE	EHEC Z0990 in O-island 36, in the same O-island as Z0985 and Z0986. Also has similarities to <i>P. syringae</i> pv. tomato effector HopPtoH.
17	NleE	27	6.3	Non-LEE	EHEC Z4329 in the same O-island 122 as Z4328, REPEC LEE-associated RorF, and <i>S. flexneri</i> ORF122.
19	NleF	24	4.7	Non-LEE	EHEC Z6020, in the same O-island 71 as Z6024. Some similarities to hypothetical proteins in <i>Yersinia pestis</i> and <i>Helicobacter pylori</i> .
20	NleG	26	5.8	Non-LEE	Peptide sequence identified: QQENAPSS(I/L)QTR. No homologue found in the database.

In addition to the five LEE-encoded effectors, we identified seven non-LEE-encoded secreted proteins that are likely effectors. These secreted proteins encoded outside the LEE were therefore designated NleA (p54), NleB, NleC, NleD, NleE, NleF, and NleG (QQENAPSS(I/L)QTR; SEQ ID NO: 59) (for non-LEE-encoded effectors) to distinguish them from LEE-encoded secreted proteins/ effectors (Esp) (Table 2). Among the seven proteins identified, only NleG was unique to *C.*

*rodentium*, and the other 6 proteins have highly conserved homologues in EHEC O157 (Table 2). The EHEC homologues are encoded by genes clustered in three discrete regions in the genome, with each region encoding at least two proteins that show homology to the *C. rodentium* secreted proteins (Table 2). The genes Z6024 and Z6020 encoding the homologues of NleA and NleF are located in EHEC O-island 71 associated with prophage CP-933P. Similarly, the genes Z4328 and Z4329 encoding the NleB and NleE homologues are located in O-island 122, and those encoding the NleC and NleD homologues (Z0986 and Z0990) are in O-island 36 (Table 2, Fig. 9). Furthermore, Z4328 (O-island 122) has strong homology to Z0985, a gene located next to Z0986 in O-island 36.

Homologues of all six new EHEC effector genes are also present and similarly organized in EPEC, whose genome is being sequenced (<http://www.sanger.ac.uk/Projects/Microbes/>). Except for Z6024, which showed 89% nucleotide identity to an EPEC gene, the other 5 EHEC genes showed greater than 95% identity to their homologues in EPEC. Moreover, some of these effectors are also highly conserved in other pathogenic bacteria. NleD/Z0990 has similarity to the type III effector HopPtoH of *P. syringae* pv. tomato (41, 42). NleE/Z4329 has significant homology to RorfD of rabbit EPEC (REPEC) and Orf212 of *S. flexneri* (8, 33), while NleB/Z4328 has strong homology to RorfE of REPEC and two hypothetical *S. typhimurium* proteins. The genes for Z4328 and Z4329 are located adjacent in EHEC, similar to the gene arrangement of *rorfD* and *rorfE* in REPEC (8). However, *rorfD* and *rorfE* are located next to the LEE in REPEC, while their counterparts in EHEC reside in a region (O-island 122) distant from the LEE. EHEC O-island 122 carrying Z4328 and Z4329 also contains genes encoding two cytotoxins as well as a homologue of PagC, an important PhoP/PhoQ-regulated virulence factor in *S. enterica* (3, 43). The three O-islands in EHEC that encode the new effectors have dinucleotide bias and low GC% contents, hallmarks of PAIs (9). In addition, they are either associated with a prophage or flanked by mobile insertion sequences, and are not present in the genome of non-pathogenic *E. coli* (3), suggesting horizontal transfer of these genes. Collectively, this suggests the importance of these islands and the newly identified *Citrobacter* and EHEC effectors in virulence. It also indicates that, as they diverge from each other, related pathogens maintain a surprisingly

conserved set of PAIs despite the varied locations of the PAIs in the bacterial chromosome.

#### EXAMPLE 4

##### Identification of NleA

Although type III-secretion is generally thought to be contact-dependent (46), defined *in vitro* culture conditions can induce EHEC to secrete type III effectors into the extracellular medium during growth in liquid culture (28, 51). Culture supernatants were prepared from wildtype EHEC (wt) and a type III secretion mutant (*escN*-), grown in type III-secretion-inducing conditions. Analysis of the secreted proteins by SDS-PAGE revealed one abundant high molecular weight protein common to the secreted proteins from both the wildtype and *escN*- samples, and several other abundant proteins unique to the wildtype sample (Figure 10A). The secreted proteins were separated by 2-dimensional gel electrophoresis and the abundant separated protein spots were excised from the gel and analyzed by mass spectrometry (Figure 10B, Table I).

Table I

Spot number	ID	e value	# of peptides	predicted mw (kDa)	experimental mw (kDa)	predicted pI	experimental pI
1	EspP	5.60E-4	4	105	95	5.9	6.5
2a	Tir	2.50E-39	14	58	68	5	5
2b	Tir	2.10E-29	10	58	65	5	4.8
3	NleA	7.70E-11	6	48	50	5	5
4a	EspB	8.60E-53	19	33	38	5.1	5.2
4b	EspB	2.00E-06	2	33	38	5.1	5.1
5	EspA	1.30E-37	16	21	18	4.8	5

Spot #1 which was present in both wildtype and *escN*- culture supernatants was identified as EspP, a plasmid-encoded protein of EHEC that is secreted by an autotransporter mechanism which is independent of type III secretion (25). Four major spots (#2, 3, 4, 5) were unique to the wildtype supernatants. Three of these spots were identified as known type III secreted proteins encoded within the LEE: Tir

(spot #2), EspB (spot #4), and EspA (spot #5) (Figure 10B, Table I). Spot #3 was identified as a protein of predicted molecular weight of 48 kDa encoded by an open reading frame within the EHEC genome but outside the LEE (Figure 10C). We called this protein NleA, for Non-LEE-encoded effector A.

5

### EXAMPLE 5

#### Characterization of the locus containing *nleA*

The *nleA* gene is encoded in an O-island: a region of the EHEC genome absent from the genome of the non-pathogenic *E. coli* strain K-12 (3). The region between  
10 the last gene conserved in the *E. coli* K12 backbone (*YciE*) and genes encoding phage structural proteins contained several putative transposase fragments and one putative site-specific recombinase fragment (Figure 11A). Analysis of this region with Islandpath, a program designed to identify PAIs (13), revealed that all ORFs within this region have a dinucleotide bias and a GC content divergent from the EHEC  
15 genome mean. 10 ORFs within the region have a GC content at least 1 standard deviation lower than the EHEC genome mean, while 2 of the 6 ORFs have GC content at least 1 standard deviation higher than the EHEC genome mean. Together, these results suggest that *nleA* is localized to a PAI containing horizontally-transferred genes. Several other ORFs within this region have features suggestive of roles in  
20 virulence including a putative chaperone (Z2565) and two proteins with similarity to type III-secreted proteins of other pathogens (Z6021, Z6020).

To investigate further the nature and distribution of the *nleA* gene, a *nleA* probe was prepared and Southern blots were performed on a panel of genomic DNA from other A/E pathogens and a non-pathogenic *E. coli* strain. As shown in Figure  
25 11B, the *nleA* gene was present in all A/E pathogens examined, but absent from non-pathogenic *E. coli*. Analysis of the in-progress EPEC genome sequence revealed that *nleA* is present in close proximity to a phage insertion site in the EPEC genome. *nleA* is also present within a prophage of an intimin-positive, non-O157 EHEC strain, O84:H4, but absent from non-pathogenic strains of *E. coli*, uropathogenic *E. coli*,  
30 which does not contain the LEE. *nleA* is also absent from other TTSS-containing pathogens such as *Salmonella* and *Shigella* species. Thus, *nleA* appears to have been specifically acquired or retained in A/E pathogens. A multiple sequence alignment of

*nleA* gene sequences from *C. rodentium*, EPEC, EHEC, and O84:H4 reveals a high degree of sequence conservation in these four A/E pathogens (Figure 11C).

#### EXAMPLE 6

##### NleA is secreted by the LEE-encoded type III secretion system

EHEC and EPEC effectors of the LEE-encoded TTSS described to date are encoded within the LEE, in close proximity to the genes encoding the secretion apparatus itself. To determine whether secretion of NleA was dependent on the LEE-encoded TTSS, an epitope-tagged version of NleA was expressed from a plasmid in wildtype EHEC and an *escN*- strain, which is deficient for type III secretion (47). As shown in Figure 12A, while HA-tagged NleA was expressed to similar levels in wildtype and *escN*- EHEC, the protein was only secreted into the extracellular media by the NleA-HA-transformed wildtype bacteria. DnaK, a non-secreted bacterial protein, was used as a control for the absence of non-secreted proteins in the secreted protein samples (Figure 12B). Tir was secreted in the untransformed and NleA-HA-transformed wildtype strains, but not secreted by the *escN*- strains (Figure 12C), verifying the expected TTSS phenotypes. Similar results were obtained for expression of epitope-tagged NleA in wildtype EPEC and several type III-secretion mutants of EPEC, indicating that NleA can also be secreted by the EPEC TTSS.

#### EXAMPLE 7

##### NleA is translocated into host cells

When EHEC is grown under type III secretion-inducing conditions, two types of proteins are secreted into the extracellular medium. To determine whether NleA was a translocator or a translocated effector, we investigated type III secretion and translocation in the absence of NleA by generating a deletion mutant strain. Secreted protein profiles from wildtype and a  $\Delta nleA$  mutant EHEC strains were analyzed. The wildtype sample contained an abundant protein of approximately 50 kDa which was absent from the  $\Delta nleA$  secreted proteins (Figure 13A). Western blot analysis with antisera directed against NleA demonstrated that 50 kDa NleA was present in the wildtype secreted proteins and absent in  $\Delta nleA$  sample (Figure 13B). However, other than the presence or absence of NleA, the secreted protein profiles of the wildtype and

*ΔnleA* strains were identical (Figure 13A). Thus, NleA is not required for secretion of other type III-secreted effectors. To determine whether NleA is required for translocation of other type III effectors into host cells, HeLa cells were infected with wildtype EHEC and EHEC *ΔnleA*, and Tir translocation and function were monitored by immunofluorescent staining of infected cells. Pedestal formation by wildtype EHEC and the *ΔnleA* mutant was examined by subjecting infected cells to immunofluorescence with anti-EHEC and anti-Tir antibodies, and visualizing filamentous actin using phalloidin. The results indicated that EHEC *ΔnleA* adhered to HeLa cells at similar levels to wildtype EHEC. Immunofluorescent staining revealed that Tir was translocated into host cells and focused under infecting bacteria in both the wildtype and *ΔnleA* EHEC strains. To confirm functional Tir translocation, infected cells were stained with fluorescent phalloidin to visualize polymerized actin involved in pedestal formation underneath adherent bacteria. Actin pedestals were evident in cells infected with either wildtype or *ΔnleA* EHEC, indicating that translocation and function of other type III effectors can proceed in the absence of NleA. These results also indicate that NleA is not required for pedestal formation.

As NleA did not appear to play a role in the secretion or translocation of other effectors, we investigated whether NleA was translocated itself. HeLa cells were infected for 6 hours with wildtype or *escN*- EHEC expressing HA-tagged NleA and subjected to subcellular fractionation and Western blot analysis with an anti-HA antibody. As indicated in Figure 14A, NleA is translocated into host cells where it associates with the host cell membrane fraction. Translocation of NleA is not observed during infection of cells with a type III secretion mutant expressing HA-tagged NleA, indicating that NleA translocation and host membrane association is TTSS-dependent. Western blotting of the fractions with antibodies to proteins specific to each fraction confirmed the absence of cross-contamination of the fractions. Calnexin, a host cell integral membrane protein, was absent from the host cytoplasmic fraction, and tubulin, a host cell cytoplasmic protein, was absent from the host membrane fraction. DnaK, a non-secreted bacterial protein, was present only in the low-speed pellet, demonstrating a lack of bacterial contamination of the host membrane and cytosolic fractions. NleA and DnaK were absent from the low speed pellet in the type-III mutant-infected cells due to the type III dependence of EHEC

adherence. To control for the artifactual absence of NleA in type III mutant-infected samples due to the type III-dependence of EHEC adherence, we also performed similar experiments expressing and delivering NleA-HA by wildtype and type III mutant EPEC, since EPEC adherence to HeLa cells is independent of type III secretion. NleA was present in the membrane fraction of cells infected with wildtype, but not type III mutant EPEC strain. Both NleA and DnaK were present in the low-speed pellet fractions of both wildtype and type III mutant EPEC infected cells.

To investigate the nature of NleA association with host cell membranes, infected host cell membrane fractions containing HA-tagged NleA were extracted on ice under several conditions and recentrifuged to obtain soluble and insoluble membrane fractions (Figure 14B). These fractions were subjected to Western blot analysis with anti-HA antibody to detect HA-tagged NleA. Treatment with high salt (1M NaCl) or alkaline pH (0.2M Na<sub>2</sub>CO<sub>3</sub>, pH 11.4) removes proteins that are peripherally associated with membranes via electrostatic or hydrophilic interactions respectively. The association of NleA with host cell membranes resisted disruption with these treatments (Figure 14B, top panel), as did calnexin, an integral membrane protein (Figure 14B, middle panel). In contrast, a significant proportion of calreticulin, a peripheral membrane protein, was extracted from the membrane fraction during both high salt and alkaline pH treatment (Figure 14B, bottom panel). Treatment of membrane fractions with the non-ionic detergent Triton X-100, which solubilizes integral membrane proteins such as calnexin (Figure 14B, middle panel), almost completely solubilized NleA, resulting in a shift of the HA-tagged NleA protein from the insoluble to soluble fraction (Figure 14B, top panel). These results indicate that NleA is translocated into host cells where it behaves as an integral membrane protein. Indeed, analysis of the NleA protein sequence by several transmembrane domain prediction programs predicts one or two putative transmembrane domains within the sequence (Figure 11C).

### EXAMPLE 8

#### NleA localizes to the host Golgi apparatus

The subcellular localization of NleA within host cells was then determined. HeLa cells were infected with wildtype EHEC or EHEC  $\Delta nleA$  and subjected to



immunofluorescence with antibodies directed against NleA and mannosidase II. Some samples were treated with brefeldin A for 30 minutes prior to fixation. Two-color overlays of the NleA and mannosidase II staining were performed. HeLa cells were transfected with an expression construct encoding a GFP-NleA fusion protein, and subjected to immunofluorescence with an antibody directed against mannosidase II.

Immunofluorescent staining of HeLa cells infected with wildtype EHEC, using the anti-NleA antibody, resulted in a perinuclear pattern of staining that was absent in cells infected with EHEC $\Delta$ *nleA*, or uninfected cells. This pattern did not resemble staining obtained with markers for late endosomes, lysosomes, ER, mitochondria, or the nucleus. However, a very similar pattern of staining was observed when cells were co-stained with anti-NleA and antibodies to markers of the Golgi apparatus, including mannosidase II, where the two proteins colocalized extensively. To confirm Golgi-localization of NleA, infected cells were incubated with brefeldin A, a fungal metabolite that disrupts Golgi structure (27), before fixation and immunofluorescence. Brefeldin A treatment caused a diffusion of both mannosidase II and NleA staining, as expected for Golgi-localized proteins. Colocalization of NleA was observed with several other markers of the Golgi apparatus, and Golgi localization was also observed in experiments examining epitope-tagged NleA stained with anti-tag antibodies, utilizing both HA and FLAG epitope tags. To determine if Golgi localization of NleA required other bacterial factors or was an inherent property of NleA, cells were transfected with an expression construct encoding a GFP-NleA fusion protein. Transfected NleA GFP also localized to the Golgi, where it overlapped with mannosidase II staining.

Thus, our results indicate that NleA localizes to the Golgi. The observation that a transfected NleA-GFP fusion protein localizes to the Golgi suggests that the NleA protein contains Golgi-targeting information, and does not require other bacterial factors to get to this destination. Bacterially-delivered NleA is also Golgi-localized.

## EXAMPLE 9

### NleA is required for virulence

The high degree of sequence conservation of NleA in A/E pathogens (Figure 11C) suggests that NleA plays a similar role in infection. *C. rodentium* is a natural pathogen of mice (53), and has been used as a model system to study A/E pathogenesis. In susceptible strains, *C. rodentium* infection is fatal, and typically causes death of infected mice between days 6 – 10 of infection (54). More resistant mouse strains do not die from *C. rodentium* infection, but become colonized and develop intestinal inflammation and colonic hyperplasia (54).

To test the role of NleA in virulence, we created a *nleA*-deleted *C. rodentium* strain and verified the absence of NleA by Western blotting total bacterial extracts with the NleA antiserum (Figure 16A). Mice were infected with equal numbers of wildtype or  $\Delta nleA$  bacteria by oral gavage. In *C. rodentium*-susceptible C3H-HeJ mice, NleA was absolutely required for virulence. All C3H-HeJ mice infected with wildtype *C. rodentium* died between day 6 and 10 of the infection (n=9), whereas all  $\Delta nleA$ -infected mice (n=13) displayed some mild disease symptoms such as soft stools but still gained weight and were active throughout the infection and survived indefinitely (Figure 16B). Furthermore, the  $\Delta nleA$ -infected mice were resistant to subsequent challenge with wildtype *C. rodentium* (n=5, figure 16B). Thus, while the  $\Delta nleA$  strain is non-pathogenic in susceptible mice, it interacts sufficiently with the host to stimulate protective immunity.

In contrast to C3H/HeJ mice, *C. rodentium* infection is not lethal for outbred NIH swiss mice. In these mice, *C. rodentium* colonization of the large intestine leads to intestinal inflammation, colonic hyperplasia and mild diarrheal symptoms. NIH swiss mice were infected with wildtype *C. rodentium* or the  $\Delta nleA$  strain and sacrificed at day 10 post infection. The mice infected with the  $\Delta nleA$  strain had, on average, a 20-fold lower *C. rodentium* titre in the colon at day 10 (Figure 16C).

Histological analysis of infected NIH swiss mouse colons was performed by infecting mice with wildtype *C. rodentium* or the  $\Delta nleA$  strain and sacrificing them at day 10 post infection. The last 0.5 cm of the colon of infected mice was fixed in 10% neutral buffered formalin, processed, cut into 3  $\mu$ m sections and stained with hematoxylin and eosin. Tissue sections for all mice were observed and photographed

using the 5X and 63X objectives. The results indicated that, in histological analyses of biopsies taken from the anal verge of infected mice, numerous bacteria were evident in the wildtype-infected tissue, but bacteria were scarce in the  $\Delta nleA$ -infected samples. All animals infected with wildtype *C. rodentium* displayed pathological signs of colonic hyperplasia, whereas all  $\Delta nleA$ -infected mice had no signs of hyperplasia. The wildtype-infected samples showed severe inflammation and hyperplasia to the extent that the intestinal lumen was no longer apparent and the external muscle layer was visibly distended, to accommodate the increased volume of epithelium. In contrast, the  $\Delta nleA$ -infected samples displayed relatively normal histology. The relative degree of intestinal inflammation and hyperplasia was also evident in the difference in colon weights at the time of sacrifice in the two groups of mice (Figure 16D). The wildtype infected mice also had larger spleens than the  $\Delta nleA$ -infected mice as reflected in splenic weights (Figure 16D).

Thus, we have demonstrated a striking effect of NleA on virulence in a mouse model of disease. In the susceptible mice, the presence of functional NleA in *C. rodentium* leads to a lethal infection within 10 days. Mice infected with a strain lacking NleA exhibit few symptoms and survive the infection indefinitely. In a more resistant mouse strain where *C. rodentium* infection is non-lethal, NleA is required for the development of colonic hyperplasia, and at day 10 of infection, there are less *nleA* mutant bacteria present in the host intestine. These studies indicate a clear effect of NleA in *C. rodentium* virulence. Our results from EHEC infection of HeLa cells demonstrate that *in vitro*, NleA does not affect adherence of bacteria to host cells or translocation of other effectors, suggesting that NleA may act at the level of resisting host clearance rather than enhancing bacterial adherence. Furthermore, the resistance of  $\Delta nleA$ -infected mice to subsequent challenge with wildtype *C. rodentium* provides evidence that a *nle* mutant strain colonizes and interacts with the host sufficiently to stimulate host immunity. This is in contrast to type III-mutants of *C. rodentium*, that do not colonize the host, and provide no protection from subsequent challenge. Thus, *nleA* mutant strains may be used as an attenuated vaccine strain.

## REFERENCES

The following publications are incorporated by reference.

1. Nataro, J. P. , and Kaper, J. B. (1998) Diarrheagenic *Escherichia coli*. *Clin Microbiol Rev* **11**: 142-201.
2. Frankel, G. , Phillips, A. D. , Rosenshine, I. , Dougan, G. , Kaper, J. B. , and Knutton, S. (1998) Enteropathogenic and enterohaemorrhagic *Escherichia coli*: more subversive elements. *Mol Microbiol* **30**: 911-921.
3. Perna, N. T. , Plunkett, G. , 3rd, Burland, V. , Mau, B. , Glasner, J. D. , Rose, D. J. , Mayhew, G. F. , Evans, P. S. , Gregor, J. , Kirkpatrick, H. A. , Posfai, G. , Hackett, J. , Klink, S. , Boutin, A. , Shao, Y. , Miller, L. , Grotbeck, E. J. , Davis, N. W. , Lim, A. , Dimalanta, E. T. , Potamousis, K. D. , Apodaca, J. , Anantharaman, T. S. , Lin, J. , Yen, G. , Schwartz, D. C. , Welch, R. A. , and Blattner, F. R. (2001) Genome sequence of enterohaemorrhagic *Escherichia coli* O157:H7. *Nature* **409**: 529-533.
4. Elliott, S. J. , Wainwright, L. A. , McDaniel, T. K. , Jarvis, K. G. , Deng, Y. K. , Lai, L. C. , McNamara, B. P. , Donnenberg, M. S. , and Kaper, J. B. (1998) The complete sequence of the locus of enterocyte effacement (LEE) from enteropathogenic *Escherichia coli* E2348/69. *Mol Microbiol* **28**: 1-4.
5. Perna, N. T. , Mayhew, G. F. , Posfai, G. , Elliott, S. , Donnenberg, M. S. , Kaper, J. B. , and Blattner, F. R. (1998) Molecular evolution of a pathogenicity island from enterohemorrhagic *Escherichia coli* O157:H7. *Infect Immun* **66**: 3810-3817.
6. Zhu, C. , Agin, T. S. , Elliott, S. J. , Johnson, L. A. , Thate, T. E. , Kaper, J. B. , and Boedeker, E. C. (2001) Complete nucleotide sequence and analysis of the locus of enterocyte Effacement from rabbit diarrheagenic *Escherichia coli* RDEC-1. *Infect Immun* **69**: 2107-2115.
7. Deng, W. , Li, Y. , Vallance, B. A. , and Finlay, B. B. (2001) Locus of enterocyte effacement from *Citrobacter rodentium*: sequence analysis and evidence for horizontal transfer among attaching and effacing pathogens. *Infect Immun* **69**: 6323-6335.

8. Tauschek, M. , Strugnell, R. A. , and Robins-Browne, R. M. (2002) Characterization and evidence of mobilization of the LEE pathogenicity island of rabbit-specific strains of enteropathogenic *Escherichia coli*. *Mol Microbiol* 44: 1533-1550.
- 5 9. Hacker, J. , and Kaper, J. B. (2000) Pathogenicity islands and the evolution of microbes. *Annu Rev Microbiol* 54: 641-679.
10. G. R. Cornelis, *J. Cell. Biol.* 158 , 401 (2002).
11. S. Gruenheid, B. B. Finlay, *Nature* 422 , 775 (2003).
12. I. Chernushevich, A. Loboda, B. Thomson, *J. Mass Spectrom* . 36 , 849  
10 (2001).
13. Hsiao, W. , Wan, I. , Jones, S. J. , and Brinkman, F. S. (2003) IslandPath: aiding detection of genomic islands in prokaryotes. *Bioinformatics* 19: 418-420.
14. Edwards, R. A. , Keller, L. H. , and Schifferli, D. M. (1998) Improved  
15 allelic exchange vectors and their use to analyze 987P fimbria gene expression. *Gene* 207: 149-157.
15. V. Sperandio, J. L. Mellies, W. Nguyen, S. Shin, J. B. Kaper, *Proc. Natl. Acad. Sci. USA* 96 , 15196 (1999).
16. J. L. Mellies, S. J. Elliott, V. Sperandio, M. S. Donnenberg, J. B. Kaper,  
20 *Mol. Microbiol* . 33 , 296 (1999).
17. K. A. Datsenko, B. L. Wanner, *Proc. Natl. Acad. Sci. USA* 97 , 6640 (2000).
18. A. Abe *et al* . , *Mol. Microbiol* . 33 , 1162 (1999).
19. S. J. Elliott *et al* . , *Mol. Microbiol* . 33 , 1176 (1999).
- 25 20. Vallance, B. A. , Deng, W. , De Grado, M. , Chan, C. , Jacobson, K. , and Finlay, B. B. (2002b) Modulation of inducible nitric oxide synthase expression by the attaching and effacing bacterial pathogen *Citrobacter rodentium* in infected mice. *Infect Immun* 70: 6424-6435.
21. V. H. Bustamante, F. J. Santana, E. Calva, J. L. Puente, *Mol. Microbiol* .  
30 39 , 664 (2001).
22. J. L. Puente, D. Bieber, S. W. Ramer, W. Murray, G. K. Schoolnik, *Mol. Microbiol* . 20 , 87 (1996).

23. T. Houthaeve, H. Gausepohl, M. Mann, K. Ashman, *FEBS Lett.* **376** , 91 (1995)
24. Z. Ziegler, *Anal. Chem.* **74** , 489A (2002).
25. Brunder, W. , Schmidt, H. , and Karch, H. (1997) EspP, a novel extracellular  
5 serine protease of enterohaemorrhagic Escherichia coli O157:H7 cleaves  
human coagulation factor V. *Mol Microbiol* **24**: 767-778.
26. Buchet, A. , Nasser, W. , Eichler, K. , and Mandrand-Berthelot, M. A.  
(1999) Positive co-regulation of the Escherichia coli carnitine pathway cai and  
fix operons by CRP and the CaiF activator. *Mol Microbiol* **34**: 562-575.
- 10 27. Chardin, P. , and McCormick, F. (1999) Brefeldin A: the advantage of being  
uncompetitivE. *Cell* **97**: 153-155.
28. DeVinney, R. , Stein, M. , Reinscheid, D. , Abe, A. , Ruschkowski, S. , and  
Finlay, B. B. (1999) Enterohemorrhagic Escherichia coli O157:H7 produces  
Tir, which is translocated to the host cell membrane but is not tyrosine  
15 phosphorylated. *Infect Immun* **67**: 2389-2398.
29. Donnenberg, M. S. , and Kaper, J. B. (1991) Construction of an eae deletion  
mutant of enteropathogenic Escherichia coli by using a positive-selection  
suicide vector. *Infect Immun* **59**: 4310-4317.
30. Gauthier, A. , de Grado, M. , and Finlay, B. B. (2000) Mechanical  
20 fractionation reveals structural requirements for enteropathogenic Escherichia  
coli Tir insertion into host membranes. *Infect Immun* **68**: 4344-4348.
31. Goosney, D. L. , DeVinney, R. , and Finlay, B. B. (2001) Recruitment of  
cytoskeletal and signaling proteins to enteropathogenic and enterohemorrhagic  
Escherichia coli pedestals. *Infect Immun* **69**: 3315-3322.
- 25 32. Griffin, P. M. , Ostroff, S. M. , Tauxe, R. V. , Greene, K. D. , Wells, J.  
G. , Lewis, J. H. , and Blake, P. A. (1988) Illnesses associated with  
Escherichia coli O157:H7 infections. A broad clinical spectrum. *Ann Intern  
Med* **109**: 705-712.
33. C. Buchrieser *et al.* , *Mol. Microbiol.* **38** , 760 (2000).
- 30 34. Galan, J. E. (2001) Salmonella interactions with host cells: type III secretion  
at work. *Annu Rev Cell Dev Biol* **17**: 53-86.

35. Kenny, B. , DeVinney, R. , Stein, M. , Reinscheid, D. J. , Frey, E. A. , and Finlay, B. B. (1997) Enteropathogenic *E. coli* (EPEC) transfers its receptor for intimate adherence into mammalian cells. *Cell* **91**: 511-520.
36. Elliott, S. J. , Krejany, E. O. , Mellies, J. L. , Robins-Browne, R. M. ,  
5 Sasakawa, C. , and Kaper, J. B. (2001) EspG, a novel type III system-secreted protein from enteropathogenic *Escherichia coli* with similarities to VirA of *Shigella flexneri*. *Infect Immun* **69**: 4027-4033.
37. Kenny, B. , and Jepson, M. (2000) Targeting of an enteropathogenic *Escherichia coli* (EPEC) effector protein to host mitochondria. *Cell Microbiol*  
10 **2**: 579-590.
38. McNamara, B. P. , Koutsouris, A. , O'Connell, C. B. , Nougayrede, J. P. ,  
Donnenberg, M. S. , and Hecht, G. (2001) Translocated EspF protein from enteropathogenic *Escherichia coli* disrupts host intestinal barrier function. *J Clin Invest* **107**: 621-629.
- 15 39. O. Marches *et al.*, *Infect. Immun.* **68** , 2171 (2000).
40. Tu, X. , Nisan, I. , Yona, C. , Hanski, E. , and Rosenshine, I. (2003) EspH, a new cytoskeleton-modulating effector of enterohaemorrhagic and enteropathogenic *Escherichia coli*. *Mol Microbiol* **47**: 595-606.
41. D. S. Guttman *et al.*, *Science* **295** , 1722 (2002).
- 20 42. T. Petnicki-Ocwieja *et al.*, *Proc. Natl. Acad. Sci. USA* **99** , 7652 (2002).
43. S. I. Miller, A. M. Kukral, J. J. Mekalanos, *Proc. Natl. Acad. Sci. USA* **86** , 5054 (1989).
44. Gruenheid, S. , DeVinney, R. , Blatt, F. , Goosney, D. , Gelkop, S. , Gish, G. D. , Pawson, T. , and Finlay, B. B. (2001) Enteropathogenic *E. coli* Tir binds Nck to initiate actin pedestal formation in host cells. *Nat Cell Biol* **3**:  
25 856-859.
45. Harlow, E. , and Lane, D. (1988) *Antibodies: a laboratory manual*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
46. Hueck, C. J. (1998) Type III protein secretion systems in bacterial pathogens  
30 of animals and plants. *Microbiol Mol Biol Rev* **62**: 379-433.

47. Jarvis, K. G. , and Kaper, J. B. (1996) Secretion of extracellular proteins by enterohemorrhagic *Escherichia coli* via a putative type III secretion system. *Infect Immun* **64**: 4826-4829.
48. Kenny, B. , Ellis, S. , Leard, A. D. , Warawa, J. , Mellor, H. , and Jepson, M. A. (2002) Co-ordinate regulation of distinct host cell signalling pathways by multifunctional enteropathogenic *Escherichia coli* effector molecules. *Mol Microbiol* **44**: 1095-1107.
49. Knodler, L. A. , Vallance, B. A. , Hensel, M. , Jackel, D. , Finlay, B. B. , and Steele-Mortimer, O. (2003) Salmonella type III effectors PipB and PipB2 are targeted to detergent-resistant microdomains on internal host cell membranes. *Mol Microbiol* **49**: 685-704.
50. Levine, M. M. , Bergquist, E. J. , Nalin, D. R. , Waterman, D. H. , Hornick, R. B. , Young, C. R. , and Sotman, S. (1978) *Escherichia coli* strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. *Lancet* **1**: 1119-1122.
51. Li, Y. , Frey, E. , Mackenzie, A. M. , and Finlay, B. B. (2000) Human response to *Escherichia coli* O157:H7 infection: antibodies to secreted virulence factors. *Infect Immun* **68**: 5090-5095.
52. Peeters, J. E. , Geeroms, R. , and Orskov, F. (1988) Biotype, serotype, and pathogenicity of attaching and effacing enteropathogenic *Escherichia coli* strains isolated from diarrheic commercial rabbits. *Infect Immun* **56**: 1442-1448.
53. Schauer, D. B. , and Falkow, S. (1993) The *eae* gene of *Citrobacter freundii* biotype 4280 is necessary for colonization in transmissible murine colonic hyperplasia. *Infect Immun* **61**: 4654-4661.
54. Vallance, B. A. , Deng, W. , Jacobson, K. , and Finlay, B. B. (2003) Host susceptibility to the attaching and effacing bacterial pathogen *Citrobacter rodentium*. *Infect Immun* **71**: 3443-3453.
55. Yoshida, S. , Katayama, E. , Kuwae, A. , Mimuro, H. , Suzuki, T. , and Sasakawa, C. (2002) *Shigella* deliver an effector protein to trigger host microtubule destabilization, which promotes Rac1 activity and efficient bacterial internalization. *Embo J* **21**: 2923-2935.



56. Deng, W. , Vallance, B. A. , Li, Y. , Puente, J. L. , and Finlay, B. B. (2003) *Citrobacter rodentium* translocated intimin receptor (Tir) is an essential virulence factor needed for actin condensation, intestinal colonization and colonic hyperplasia in micE. *Mol Microbiol* **48**: 95-115.
- 5 57. "Remington's Pharmaceutical Sciences" (19<sup>th</sup> edition), ed. A. Gennaro, 1995, Mack Publishing Company, Easton, Pa.
58. Abe, A., U. Heczko, R. Hegele, and B. Finlay. 1998. Two enteropathogenic *Escherichia coli* type III secreted proteins, EspA and EspB, are virulence factors. *Journal of Experimental Medicine* **188**:1907-1916
- 10 59. *Adv. DrugDeliv. Rev.* **5** (3): 163-187 (1990)
60. Altschul, S.F. 1991. "Amino acid substitution matrices from an information theoretic perspective." *Journal of Molecular Biology*, **219**: 555-665
61. Ausubel *et al.*, *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, N.Y., 1998
- 15 62. Babiuk *et al.* (1986) *Virology* **159**: 57-66).
63. Beuzon, C. R., and D. W. Holden. 2001. Use of mixed infections with *Salmonella* strains to study virulence genes and their interactions *in vivo*. *Microbes Infect* **3**:1345-52.
64. Brown D, *et al.* (2002) *TechNotes* **9**: 3-5
- 20 65. Brummelkamp TR, *et al.* (2002) *Science* **296**:550-553
66. Canil, C., I. Rosenshine, S. Ruschkowski, M. S. Donnenberg, J. B. Kaper, and B. B. Finlay. 1993. Enteropathogenic *Escherichia coli* decreases the transepithelial electrical resistance of polarized epithelial monolayers. *Infect Immun* **61**:2755-62
- 25 67. Caplen NJ, *et al.* (2001) *Proc. Natl. Acad. Sci. USA* **98**: 9746-9747
68. *Clin. Exp. Immunol.* **78** (2): 256-262 (1989)
69. *Cloning Vectors: A Laboratory Manual* (P. H. Pouwels *et al.*, 1985, Supp. 1987
70. Dayhoff, M.O., Schwartz, R.M., Orcutt, B.C. 1978. "A model of evolutionary change in proteins." In "Atlas of Protein Sequence and Structure" **5**(3) M.O. Dayhoff (ed.), 345 - 352, National Biomedical Research Foundation, Washington
- 30

71. Eisenberg *et al.* (*J. Mol. Bio.* 179:125-142, 184
72. Elder *et al.*, *Proc. Natl. Acad. Sci. USA* (2000) 97: 2999
73. Epitope Mapping Protocols in *Methods in Molecular Biology*, Vol. 66 (Glenn E. Morris, Ed., 1996) Humana Press, Totowa, NJ
- 5 74. Fey *et al.*, *Emerg. Infect. Dis.* (2000) Volume 6
75. Gall, D. (1966) *Immunology* 11: 369-386
76. Geysen *et al.* (1984) *Proc. Natl. Acad. Sci. USA* 81 : 3998-4002
77. Geysen *et al.* (1986) *Molec. Immunol.* 23 : 709-715
78. Hammerling *et al.*, In *Monoclonal Antibodies and T Cell Hybridomas*,  
10 Elsevier, N.Y., 1981
79. Hammond SM; *et al.* (2001) *Nature Rev Gen* 2: 110-119
80. Hauf, N., and T. Chakraborty. 2003. Suppression of NF-kappa B activation and proinflammatory cytokine expression by Shiga toxin-producing *Escherichia coli*. *J Immunol* 170:2074-82
- 15 81. Hopp *et al.*, *Proc. Natl. Acad. Sci USA* (1981) 78 : 3824-3828
82. *Immunology* 58 (2): 245-250 (1986)
83. *Int. Arch. Allergy Appl. Immunol.* 68 (3) : 201-208 (1982)
84. *J Immunol. Methods* 97 (2): 159-164 (1987)
85. *J. Controlled Release* 7: 123-132 (1988)
- 20 86. Karlin, S. and Altschul, S.F. 1990. "Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes" *Proc. Natl. Acad. Sci. USA.* 87: 2264 - 2268.
87. Knodler, L. A., J. Celli, W. D. Hardt, B. A. Vallance, C. Yip, and B. B. Finlay. 2002. *Salmonella* effectors within a single pathogenicity island are  
25 differentially expressed and translocated by separate type III secretion systems. *Mol Microbiol* 43:1089-103
88. Kodak Laboratory Chemicals Bulletin 56 (1) : 1-5 (1986)
89. Kohler *et al.*, *Eur. J. Immunol.* 6:292, 1976
90. Kohler *et al.*, *Eur. J. Immunol.* 6:511, 1976
- 30 91. Kohler *et al.*, *Nature* 256:495, 1975
92. Kyte *et al.*, *J : Mol. BioL* (1982) 157: 105-132).
93. Lee NS, *et al.* (2002) *Nature Biotechnol.* 20:500-505

94. M.S. Johnson and J.P. Overington. 1993. "A Structural Basis of Sequence Comparisons: An evaluation of scoring methodologies." *Journal of Molecular Biology*. 233: 716 - 738.
95. Miyagishi M, and Taira K. (2002) *Nature Biotechnol.* 20:497-500
- 5 96. Myers and Miller, CABIOS, 1989, 4:11-17
97. Naylor, S. W., J. C. Low, T. E. Besser, A. Mahajan, G. J. Gunn, M. C. Pearce, I. J. McKendrick, D. G. Smith, and D. L. Gally. 2003. Lymphoid follicle-dense mucosa at the terminal rectum is the principal site of colonization of enterohemorrhagic *Escherichia coli* O157:H7 in the bovine host. *Infect Immun* 10 71:1505-12
98. Paddison PJ, *et al.* (2002). *Genes & Dev.* 16:948-958
99. Paul CP, *et al.* (2002) *Nature Biotechnol.* 20:505-508
100. Schijns *et al.*, *Curr. Opi. Immunol.* (2000) 12: 456
101. Sharp PA. (2001) *Genes Dev* 15: 485-490
- 15 102. States, D.J., Gish, W., Altschul, S.F. 1991. "Improved Sensitivity of Nucleic Acid Database Search Using Application-Specific Scoring Matrices" *Methods: A companion to Methods in Enzymology* 3(1): 66 – 77
103. Steven Henikoff and Jorja G. Henikoff. 1992 "Amino acid substitution matrices from protein blocks." *Proc. Natl. Acad. Sci. USA*. 89(biochemistry): 20 10915 – 10919
104. Steven Henikoff and Jorja G. Henikoff. 1993. "Performance Evaluation of Amino Acid Substitution Matrices." *Proteins: Structure, Function, and Genetics*. 17: 49- 61
105. Sui G, *et al.* (2002) *Proc. Natl. Acad. Sci. USA* 99:5515-5520
- 25 106. Vallance, B. A., W. Deng, L. A. Knodler, and B. B. Finlay. 2002. Mice lacking T and B lymphocytes develop transient colitis and crypt hyperplasia yet suffer impaired bacterial clearance during *Citrobacter rodentium* infection. *Infect Immun* 70:2070-81
107. Van Donkersgoed *et al.*, *Can. Vet. J.* (1999) 40: 332
- 30 108. Van Donkersgoed *et al.*, *Can. Vet. J.* (2001) 42: 714
109. Yu J-Y, *et al.* (2002) *Proc. Natl. Acad. Sci. USA* 99:6047-6052

110. Sambrook et al., Molecular Cloning: A Laboratory Manual. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989
111. Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, 1994
112. Vaughan *et al.*, Nature Biotech 14:309-314, 1996
113. Larsson A et al Chicken antibodies: taking advantage of evolution--a review. Poult Sci. 1993 Oct;72(10):1807-12.
114. Alymova IV, Kodihalli S, Govorkova EA, Fanget B, Gerdil C, Webster RG. Immunogenicity and protective efficacy in mice of influenza B virus vaccines grown in mammalian cells or embryonated chicken eggs. J Virol. 1998 May;72(5):4472-7.
115. O'Farrelly C, Branton D, Wanke CA. Oral ingestion of egg yolk immunoglobulin from hens immunized with an enterotoxigenic Escherichia coli strain prevents diarrhea in rabbits challenged with the same strain. Infect Immun. 1992 Jul;60(7):2593-7.
116. Romito M, Viljoen GJ, Du Plessis DH. Eliciting antigen-specific egg-yolk IgY with naked DNA. Biotechniques. 2001 Sep;31(3):670, 672, 674-5.
117. Yokoyama H, Umeda K, Peralta RC, Hashi T, Icatlo FC Jr, Kuroki M, Ikemori Y, Kodama Y. Oral passive immunization against experimental salmonellosis in mice using chicken egg yolk antibodies specific for Salmonella enteritidis and S. typhimurium. Vaccine. 1998 Feb;16(4):388-93.

#### OTHER EMBODIMENTS

Although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in

accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way.

Accession numbers, as used herein, refer to Accession numbers from multiple

5 databases, including GenBank, the European Molecular Biology Laboratory (EMBL), the DNA Database of Japan (DDBJ), or the Genome Sequence Data Base (GSDB), for nucleotide sequences, and including the Protein Information Resource (PIR), SWISSPROT, Protein Research Foundation (PRF), and Protein Data Bank (PDB) (sequences from solved structures), as well as from translations from annotated  
10 coding regions from nucleotide sequences in GenBank, EMBL, DDBJ, or RefSeq, for polypeptide sequences. Numeric ranges are inclusive of the numbers defining the range. In the specification, the word "comprising" is used as an open-ended term, substantially equivalent to the phrase "including, but not limited to", and the word "comprises" has a corresponding meaning. Citation of references herein shall not be  
15 construed as an admission that such references are prior art to the present invention. All publications are incorporated herein by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein and as though fully set forth herein. The invention includes all embodiments and variations substantially as hereinbefore described and with reference to the examples  
20 and drawings.